HSCI 485 · Lesson 6

Safety, Screening and Risk Management

Psychedelic-Assisted Medicine: Science and Practice

Learning objectives for this lesson:

  1. Describe the acute effects of psilocybin, MDMA and esketamine on blood pressure and heart rate, and explain how protocols time their monitoring.
  2. Explain how MDMA causes hyperthermia and hyponatremia, and why these harms concentrate in settings outside clinics.
  3. Calculate a corrected QT interval and explain how ibogaine's effects on the heart relate to the deaths reported in unregulated settings.
  4. Weigh the evidence linking 5-HT2B receptors to valvular heart disease with repeated dosing, and describe ketamine-associated cystitis.
  5. Summarize the evidence on psychosis, mania, suicidality, hallucinogen persisting perception disorder and extended difficulties, distinguishing trial findings from population and survey findings.
  6. Calculate a risk difference, a relative risk and a number needed to harm from published adverse event counts, and interpret their confidence intervals.
  7. Apply psychiatric and medical exclusion criteria, thresholds and medication review to referrals, distinguishing deferral from exclusion and identifying criteria that may exclude people unfairly.
  8. Describe the stepwise management of difficult experiences and medical events, discharge criteria and aftercare, including follow-up for suicidality.
  9. Describe the peer support and sanctuary services available outside clinics and what each can and cannot do, and state the legal protections and limits that apply in Canada, including those on regulated practitioners.

This course was developed by Dr. Kiffer G. Card.

Lesson 6 · HSCI 485

Safety, Screening and Risk Management

A short guided walkthrough before you work through the lesson at your own pace.

Psychedelic-Assisted Medicine: Science and Practice
Three ideas

What holds the lesson together

Risk and severity

How likely a harm is and how bad it is are separate questions.

Two settings

Screened trial participants differ from people using psychedelics in everyday life.

Uneven evidence

Serious adverse events in about 4 percent of patient participants, and systematic harm tracking in about a quarter of recent studies (Hinkle et al., 2024).

The road map

Four sections

1 · Physical risks

Blood pressure, MDMA toxicity, ibogaine, heart valves and the bladder.

2 · Psychiatric risks

Psychosis, mania, suicidality, HPPD and extended difficulties.

3 · Screening and eligibility

Exclusion criteria, thresholds, stabilization and fair access.

4 · Managing events

De-escalation, emergencies, aftercare and support outside clinics.

Before you begin

Facts about risk and how it is managed

The lesson describes risks, safeguards and services, and gives no advice on using any drug.

Sections that discuss deaths or suicidality open with a content note and support lines, including the 9-8-8 Suicide Crisis Helpline.

Section 1 of 5

Physical Risks: Blood Pressure, MDMA Toxicity, Ibogaine, Heart Valves and the Bladder

⏱ Estimated reading time: 40 minutes
Section 1 of 5

Physical Risks

Blood pressure, MDMA toxicity, ibogaine, heart valves and the bladder.

Blood pressure

Monitoring is timed to the drug

19 mmHgPooled mean systolic rise with psilocybin in supervised studies, largest at 60 to 90 minutes
33%Healthy participants above 160 mmHg systolic in nine pooled MDMA studies
2 hoursMinimum blood pressure monitoring after each esketamine dose, per the 2026 label

Sources: a narrative review (Szarpak et al., 2026); pooled laboratory studies (Vizeli & Liechti, 2017); esketamine prescribing information (Janssen, 2026).

MDMA outside clinics

Heat and water

Hyperthermia

More heat is made and less is lost; heat, crowding and exertion add to it (Parrott, 2012).

Hyponatremia

Vasopressin release, thirst and heavy fluid intake dilute blood sodium (Campbell & Rosner, 2008).

The harm comes from the drug, the person and the setting together.

The QT interval

Correcting for heart rate

Corrected QT interval (RR in seconds)
\[ \mathrm{QTc}_{\text{Bazett}} = \frac{\mathrm{QT}}{\sqrt{\mathrm{RR}}} \qquad \mathrm{QTc}_{\text{Fridericia}} = \frac{\mathrm{QT}}{\sqrt[3]{\mathrm{RR}}} \]

A QTc above 500 ms is highly abnormal (Drew et al., 2010).

Ibogaine

A risk that outlasts the experience

Mechanism

hERG channel block in cell studies; the metabolite noribogaine lasts for days (Koenig & Hilber, 2015).

One hospital study

QTc passed 500 ms in 7 of 14 monitored participants; no torsades de pointes was seen (Knuijver et al., 2022).

Deaths

Most of 19 deaths from 1990 to 2008 involved heart disease or other drugs (Alper et al., 2012).

A 2026 review describes the cardiac risk as rare but clinically significant (Brunt, 2026).

Repeated use

Heart valves and the bladder

5-HT2B and valves

Plausible from cell studies; valve changes in 8 of 29 people with repeated MDMA use in one small study (Droogmans et al., 2007); a potential risk of psychedelic microdosing that needs study (Tagen et al., 2023).

Ketamine cystitis

Described in people in Toronto who used ketamine daily (Shahani et al., 2007); little sign of raised urinary risk in psychiatric treatment, on limited data (Kerr-Gaffney et al., 2025).

Carry forward

Predictable risks, managed by design

  • Physical risks rise with dose, frequency and pre-existing heart disease.
  • Screening and timed monitoring reduce them.
  • Section 2 turns to psychiatric risks, which are harder to predict.

Content note

This section discusses deaths associated with ibogaine and with MDMA used outside clinics. Support is available at any time from the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8) and, for Indigenous people across Canada, the Hope for Wellness Help Line (1-855-242-3310).

Introduction

Lesson 3 described how psychedelics act on receptors and how the body absorbs, converts and clears them. This lesson asks what can go wrong, for whom, and how clinicians reduce the chance that it does, taking physical risks, psychiatric risks, screening and the management of events in turn.

Learning Objectives

  • 1.1 Describe the acute effects of psilocybin, MDMA and esketamine on blood pressure and heart rate, and explain how clinical protocols monitor them.
  • 2.1 Explain how MDMA can cause hyperthermia and hyponatremia, and why these risks concentrate in settings outside clinics.
  • 3.1 Explain how ibogaine prolongs the QT interval, calculate a corrected QT interval with the Bazett and Fridericia formulas, and summarize the evidence on deaths associated with ibogaine.
  • 4.1 Describe the 5-HT2B receptor hypothesis of drug-induced valvular heart disease and weigh the evidence that links it to repeated psychedelic or MDMA use.
  • 4.2 Describe ketamine-associated cystitis and explain how its risk depends on dose and frequency of use.

A risk is the probability that a harm occurs, and its severity is how bad the harm is: a brief rise in blood pressure during a psilocybin session is common and mild, while a fatal heart rhythm after ibogaine is rare and catastrophic. Trial participants are screened, dosed and monitored, while most people who use psychedelics do so outside any clinic, so evidence from one setting does not transfer automatically to the other. The safety evidence is also uneven. A meta-analysis of 114 studies of classic psychedelics with 3,504 participants found no serious adverse events among healthy participants and serious adverse events in about 4 percent of participants with pre-existing neuropsychiatric conditions, and only 16 of the 68 analyzed studies published since 2005 (23.5 percent) described systematic assessment of adverse events (Hinkle et al., 2024). An earlier review of 44 clinical studies with 598 patients, which also included MDMA, likewise judged adverse events to be poorly defined and probably under-reported (Breeksema et al., 2022). Table 6.1 previews the physical risks in this section.

Table 6.1. The main physical risks examined in Section 1, with the mechanism behind each and the setting in which reported harms concentrate.

AgentPhysical riskMechanism in briefWhere harms concentrate
Psilocybin, MDMA, esketamineTransient rises in blood pressure and heart rateSympathetic (fight or flight) activationPeople with heart or vascular disease
MDMAHyperthermia and hyponatremiaMore heat made and less lost; vasopressin release with heavy fluid intakeHot, crowded events outside clinics
IbogaineQT prolongation, arrhythmia and deathBlock of the hERG potassium channelUnregulated settings; people with heart disease or other drug use
MDMA and possibly classic psychedelicsValvular heart diseaseActivation of 5-HT2B receptors on valve cellsChronic heavy or repeated use
KetamineUlcerative cystitisInflammation of the bladder liningFrequent, high-dose non-medical use

1.1 Blood Pressure and Heart Rate

Most of the drugs in this course raise blood pressure and heart rate for a few hours, as part of the activation of the sympathetic nervous system that Lesson 3 explains. In healthy participants the rise is usually modest and brief; in people with uncontrolled hypertension or heart disease it carries more risk, which is why trials have excluded them (Johnson, Richards & Griffiths, 2008; Vizeli & Liechti, 2017). The box below defines the terms used to describe these changes.

Reading blood pressure and heart rate

Systolic blood pressure is the pressure in the arteries when the heart contracts, and diastolic blood pressure is the pressure between beats. Both are measured in millimetres of mercury (mmHg) and written as, for example, 120/80 mmHg.

Tachycardia is a heart rate above 100 beats per minute, and an excursion is a temporary rise above a set threshold during a session.

1.1.1 Psilocybin

A 2026 analysis pooled 536 psilocybin sessions (oral doses of 20 to 47 mg) among 368 participants in 14 studies at Johns Hopkins University since 1999; it was posted as a preprint in April 2026 and, as of October 2026, had not been peer reviewed (Nayak et al., 2026). The median peak systolic pressure was 145 mmHg, a median rise of 22 mmHg, reached about 90 minutes after the dose and close to baseline again by 300 minutes. Systolic pressure exceeded 170 mmHg in 6.0 percent of sessions and 180 mmHg in 3.2 percent, for medians of 8.5 and 10 minutes respectively, and staff gave antihypertensive medicine in one session. A 2026 narrative review reported pooled mean increases in supervised studies of about 19.0 mmHg systolic and 8.7 mmHg diastolic, largest about 60 to 90 minutes after dosing, and cautioned that the picture may change for people with heart disease, people taking interacting medicines and mushroom products whose alkaloid content varies more than tenfold (Szarpak et al., 2026).

1.1.2 MDMA and Esketamine

MDMA's effects are larger. In nine pooled laboratory studies in which 166 healthy participants received 75 or 125 mg, systolic pressure rose above 160 mmHg in 33 percent, heart rate above 100 beats per minute in 29 percent and body temperature above 38°C in 19 percent, more often after the higher dose; no serious adverse events occurred, and the authors judged the risks likely to be higher in people with cardiovascular disease (Vizeli & Liechti, 2017). For esketamine, the nasal spray sold as Spravato (Lesson 8), the prescribing information states that blood pressure rises at all recommended doses, peaks about 40 minutes after a dose and lasts about four hours, and that 3 to 19 percent of treated patients had rises of at least 40 mmHg systolic or 25 mmHg diastolic in the first four weeks, compared with 1 to 4 percent on placebo (Janssen, 2026). Clinicians measure blood pressure before each dose, weigh the risk above about 140/90 mmHg, measure again at about 40 minutes and monitor for at least two hours. Figure 6.1 compares the two time courses with their monitoring windows.

Blood pressure response and monitoring window Psilocybin pooled sessions peak about 90 min near baseline by 300 min measured at least hourly to 360 min Esketamine product label peak about 40 min, lasts about 4 h monitor at least 2 h 0 h1 h2 h3 h4 h5 h6 h
Figure 6.1. The blood pressure response to psilocybin (pooled Johns Hopkins sessions; Nayak et al., 2026, preprint) and to esketamine (product prescribing information; Janssen, 2026), shown with the measurement schedule or monitoring requirement for each.

Monitoring is timed to the drug: a protocol that measured blood pressure only at the start and end of a psilocybin session would miss the peak at 90 minutes. Section 3 returns to the thresholds that decide eligibility. The next risks arise mainly outside clinics.

2.1 MDMA, Body Temperature and Water Balance Outside Clinics

Two serious harms of MDMA arise from its effects on the body's control of heat and water; neither is common, and both can be fatal. Hyperthermia is a rise in core body temperature above its normal range. In placebo-controlled laboratory studies, moderate doses of MDMA raised body temperature by about 0.4°C and higher doses by about 0.7°C, while some studies of people using MDMA in dance clubs found average increases above 1.0°C, which Parrott (2012) attributed to activity, heat and overcrowding. MDMA increases heat production and delays sweating, and in rare cases moderate hyperthermia progresses to severe hyperpyrexia (very high fever) for reasons that are not well understood (Parrott, 2012). Hall and Henry (2006) describe hyperpyrexia with multi-organ failure as a relatively well known form of acute MDMA toxicity.

Hyponatremia is an abnormally low concentration of sodium in the blood. Campbell and Rosner (2008) describe a "perfect storm": MDMA causes release of arginine vasopressin, the hormone that tells the kidneys to retain water, and increases thirst, while fluids are easy to obtain at events and people are told to drink a great deal. The blood becomes diluted, and the authors report serious hyponatremia and hyponatremia-associated deaths. Figure 6.2 sets out the two pathways.

Temperature More heat made,less heat lost,sweating delayed Heat, crowdingand exertionadd heat stress Hyperthermia(raised coretemperature) Rarely, severehyperpyrexia andorgan failure Water balance Vasopressinreleased: kidneyskeep more water Thirst and heavyfluid intakeadd water Blood sodiumdiluted(hyponatremia) Serious illnessand deathsreported Dashed boxes mark contributions of the setting; solid boxes mark effects of the drug and their results.
Figure 6.2. Two pathways by which MDMA can cause serious harm, drawn from Parrott (2012), Hall and Henry (2006) and Campbell and Rosner (2008); the dashed boxes show how the setting adds to the effects of the drug.

The figure shows why the same drug carries different risks in different places. In the laboratory studies, participants rested, received a known dose and had their temperature measured, and even so 19 percent exceeded 38°C (Vizeli & Liechti, 2017). At a festival, a person may take a product of unknown content and strength, more than once, while dancing in heat and crowds. The harm thus arises from the combination of drug, person and setting. Clinical protocols act on all three, by fixing the dose, screening out people with heart disease and controlling the environment, while outside clinics harm reduction services work on the parts they can change. HSCI 402 develops drug checking, and Section 4 describes the peer support and sanctuary services at Canadian events.

3.1 Ibogaine, the QT Interval and Deaths

Ibogaine is an alkaloid from the root bark of the iboga shrub, used ceremonially in the Bwiti religion of West Central Africa (Lesson 2) and, around the world, in medical and non-medical settings for opioid detoxification and other substance use (Alper, Stajić & Gill, 2012). Lesson 10 examines its evidence in opioid use disorder. Its main physical danger is a disturbance of the heart's electrical recovery that appears on the electrocardiogram (ECG) as a long QT interval.

3.1.1 The QT Interval

On an ECG, the QRS complex marks the electrical activation of the ventricles, the heart's main pumping chambers, and the T wave marks their recovery, called repolarization. The QT interval runs from the start of the QRS complex to the end of the T wave (Figure 6.3).

PQRST RR interval (time for one beat) QT interval QRS: ventricles activate T wave: ventricles recover
Figure 6.3. A schematic electrocardiogram of two heartbeats, showing the QT interval and the RR interval used to correct it for heart rate.

The QT interval shortens as the heart beats faster, so it is corrected to a standard heart rate before it is compared with a threshold. The corrected value, QTc, divides the measured QT by a function of the RR interval, the time in seconds from one beat to the next. Equation 6.1 gives the two corrections in most common use.

Corrected QT interval
RR = 60 ÷ heart rate;   QTc (Bazett) = QT ÷ √RR;   QTc (Fridericia) = QT ÷ ∛RREq 6.1
The RR interval in seconds equals 60 divided by the heart rate in beats per minute. Bazett's correction divides the measured QT interval in milliseconds by the square root of the RR interval, and Fridericia's correction divides it by the cube root.

At 60 beats per minute both corrections leave the QT unchanged; at faster rates they diverge. A scientific statement from the American Heart Association and the American College of Cardiology Foundation notes that Bazett's formula tends to give overlong values above about 85 beats per minute, treats a QTc above about 470 ms in males and 480 ms in females as prolonged, describes a QTc above 500 ms as highly abnormal (associated with a two- to threefold higher risk of a dangerous arrhythmia in congenital long QT syndrome), and advises prompt action when a drug lengthens the QTc by 60 ms or more (Drew et al., 2010).

Worked Example 6.1. A hypothetical screening ECG shows a QT interval of 440 ms at 72 beats per minute. RR = 60 ÷ 72 = 0.833 s. Bazett's QTc = 440 ÷ √0.833 = 440 ÷ 0.913 = 482 ms. Fridericia's QTc = 440 ÷ ∛0.833 = 440 ÷ 0.941 = 468 ms. The 14 ms difference can place the same tracing on either side of a 470 ms threshold. Use Calculator 6.1 to check these figures and to see the gap widen as heart rate rises.

3.1.2 How Ibogaine Affects the Heart

Studies in cells show that ibogaine and its main metabolite, noribogaine, inhibit the hERG potassium channel, which carries the current that repolarizes heart muscle cells (Koenig & Hilber, 2015; Knuijver et al., 2022). Slower repolarization lengthens the QT interval and raises the risk of torsades de pointes, a fast, irregular ventricular rhythm that can be life-threatening. Koenig and Hilber (2015) report a plasma half-life of 4 to 7 hours for ibogaine and 28 to 49 hours for noribogaine, so the cardiac risk can outlast the acute experience by days. Ibogaine can also slow the heart and lower blood pressure, which adds to the risk (Knuijver et al., 2022). Case 6.1 shows these effects under close monitoring.

Case 6.1: Monitoring ibogaine in a Dutch university hospital

Knuijver and colleagues (2022) gave a single dose of ibogaine hydrochloride (10 mg per kg) to 14 people with opioid use disorder on opioid maintenance treatment. They excluded people with heart disease, a QTc above 450 ms (men) or 470 ms (women) or QT-prolonging medicines, and recorded 12-lead ECGs at regular intervals for at least 24 hours, with magnesium planned for any QTc above 500 ms. Before dosing, participants were switched from their maintenance opioid to oral morphine for eight days, partly to remove any QT-prolonging effect of methadone.

The maximum QTc prolongation (Fridericia) was about 95 to 100 ms in a typical participant: the abstract gives an average of 95 ms (range 29 to 146), and the results table a median of 102 ms (range 40 to 168). Half of the participants exceeded 500 ms, and in 6 of 14 the QTc stayed above 450 ms beyond 24 hours. No torsades de pointes was observed, although the authors note that their ECG monitoring was not continuous and could have missed brief episodes, and all participants had severe, temporary ataxia (loss of coordination). The authors concluded that ibogaine belongs only in controlled settings with strict cardiac monitoring, and noted that the heart and liver disease they excluded is common among people with long-term illicit opioid use.

3.1.3 Deaths Associated with Ibogaine

Alper, Stajić and Gill (2012) reviewed every known death outside West Central Africa temporally related to ibogaine between 1990 and 2008. Nineteen people, 15 men and 4 women aged 24 to 54, died between 1.5 and 76 hours after taking it. In 12 of the 14 cases with adequate post-mortem data, advanced pre-existing medical conditions, mainly cardiovascular, or other drugs explained or contributed to the death. Other risk factors were seizures linked to alcohol or benzodiazepine withdrawal and the uninformed use of ethnopharmacological forms of ibogaine. A 2026 review describes the cardiac risk as rare but clinically significant and notes case reports of dangerous arrhythmias at therapeutic doses and in people without pre-existing heart conditions (Brunt, 2026). Health Canada issued a public warning in 2015 and added ibogaine to the Prescription Drug List in May 2017, citing serious and fatal adverse reaction reports (Health Canada, 2017). Lesson 10 describes trials that give ibogaine with magnesium.

4.1 5-HT2B Receptors and the Valvulopathy Question

The fourth risk would develop over months or years of repeated exposure, and it rests on a chain of reasoning from cells to people. It began with fenfluramine, an appetite suppressant later withdrawn from that use, which was linked to drug-induced valvular heart disease, in which damaged heart valves leak or narrow (Setola et al., 2003). Rothman and colleagues (2000) found that the drugs known to cause it all activated the 5-HT2B receptor, concluded that such activation is probably necessary for the disease, and recommended screening every serotonergic medicine for it. Setola and colleagues (2003) then showed that MDMA and its metabolite MDA activate human 5-HT2B receptors and make human valve cells proliferate in culture, and predicted that long-term MDMA use could cause fenfluramine-like valve disease.

Evidence in people is limited. Droogmans and colleagues (2007) examined 29 people with a history of MDMA use and 29 matched controls with blinded echocardiography (heart ultrasound); 8 of the 29 people with a history of MDMA use (28 percent) and none of the controls had abnormal valves, mostly mild to moderate regurgitation (backflow). Tagen and colleagues (2023) found that LSD, psilocybin, mescaline, DMT and MDMA or their metabolites all bind the 5-HT2B receptor at least as potently as the 5-HT2A receptor, and that all except mescaline, which could not be assessed, are partial agonists. Safety margins at typical microdoses were wider than for known valve-damaging drugs, and the authors judged valve disease a potential risk of chronic microdosing that needs study. A 2026 review judged a valve concern biologically plausible for psilocybin under chronic exposure, while noting that clinical valve injury has not been established (Szarpak et al., 2026). Table 6.2 sets out what each kind of evidence can show.

Table 6.2. The evidence on 5-HT2B receptors and valvular heart disease, by kind of study.

StudyKind of evidenceWhat it can and cannot show
Rothman et al. (2000)Receptor screening in cellsA plausible mechanism
Setola et al. (2003)Human valve cells in cultureThe mechanism can operate; dose, time and the whole body are absent
Droogmans et al. (2007)Cross-sectional study, 29 people with a history of MDMA use and 29 controlsPossible harm with repeated use; small and measured once
Tagen et al. (2023)Review of cell, animal and clinical dataThe evidence gap for repeated dosing

Trials of psychedelic-assisted therapy give one to three doses, so the question presses most for microdosing, frequent maintenance sessions and heavy long-term MDMA use. A prospective study measuring heart valves before and during repeated dosing would test the hypothesis directly, and Tagen and colleagues (2023) found no animal or clinical study designed to evaluate this risk for the classic psychedelics. For these drugs the valve risk therefore remains largely speculative, resting on cell studies and on evidence from repeated MDMA use, and research on it is evolving. The flip cards apply Lesson 4's rule that findings in cells need confirmation in people.

What a cell study can showClick to explore
What a cross-sectional study can showClick to explore

4.2 Ketamine and the Bladder

An early description of the last physical risk came from Toronto, in 2007. Shahani and colleagues (2007), at St. Michael's Hospital and the University of Toronto, described nine people who used ketamine daily and had severe pain on urination, frequency, urgency and visible blood in the urine. Urine cultures were sterile, imaging showed thickened bladder walls and small capacity, and cystoscopy showed severe ketamine-associated ulcerative cystitis, an inflammation that strips the bladder lining. Stopping ketamine, with the bladder medicine pentosan polysulfate, appeared to give some relief.

In an online survey promoted by a dance music magazine, 1,285 of 3,806 respondents reported ketamine use in the past year, and 26.6 percent of them reported urinary symptoms, which increased with both dose and frequency of use; of 251 who described the course of their symptoms, 51 percent reported improvement after stopping (Winstock et al., 2012). Because the sample was self-selected, these percentages describe respondents only. Medical use involves lower and less frequent doses. The esketamine prescribing information reports cystitis with long-term off-label ketamine use, no esketamine-related interstitial cystitis in its studies, and more lower urinary tract symptoms than with placebo (Janssen, 2026), and reports to the United States adverse event reporting system show higher odds of urinary disorders for ketamine than for other drug classes and lower or comparable odds for esketamine (Chiappini et al., 2025). A 2025 systematic review of 27 studies of ketamine treatment for psychiatric disorders found urological symptoms in 0 to 24.5 percent of patients, mostly mild or moderate, and concluded that, on the limited data available, treatment does not appear to raise the risk, although few studies assessed long-term treatment or monitored symptoms systematically (Kerr-Gaffney et al., 2025). Lesson 8 describes ketamine-assisted psychotherapy and private ketamine clinics, where repeated dosing schedules raise this question. Try it 6.1 asks you to match each risk in this section to its safeguards.

Try it 6.1: Matching safeguards to physical risks

For each risk in Table 6.1, name one safeguard that a clinical protocol uses and say whether it is available at a music festival.

Suggested answer: Screening for hypertension and timed blood pressure measurement have no festival equivalent. A clinic fixes the MDMA dose, keeps the person at rest and measures temperature (Vizeli & Liechti, 2017), while heat, crowds and unknown doses add risk at a festival. A hospital screens the ECG and monitors the heart for a day or more after ibogaine (Knuijver et al., 2022). For valve disease, the safeguard is to limit repeated exposure until evidence exists (Tagen et al., 2023), and for cystitis, medical regimens use lower and less frequent doses and monitor urinary symptoms (Janssen, 2026); both depend at a festival on the person's own pattern of use.

Most physical risks of psychedelics follow predictably from their pharmacology: they rise with dose and frequency, they are larger in people with heart disease, and the setting shapes them. Screening and monitoring reduce them, and most of the deaths reviewed here involved pre-existing illness, other drugs or settings without those safeguards, although arrhythmias after ibogaine have also been reported in people without known heart disease (Brunt, 2026). Psychiatric risks are harder to predict, because they depend on the person's history and on the experience itself, and Section 2 examines them.

Key Takeaways

  • 1.1 Psilocybin, MDMA and esketamine raise blood pressure and heart rate for a few hours through sympathetic activation, and trials exclude people with uncontrolled hypertension or heart disease. In pooled Johns Hopkins sessions reported in a 2026 preprint, psilocybin raised systolic pressure by a median of 22 mmHg, with a peak at about 90 minutes and a return near baseline by 300 minutes, while esketamine's rise peaks at about 40 minutes and lasts about four hours. Monitoring must therefore be timed to the drug.
  • 2.1 MDMA can cause hyperthermia by increasing heat production and delaying sweating, and hyponatremia by releasing vasopressin and increasing thirst while fluids are freely available. Heat, crowding, exertion, heavy fluid intake and products of unknown content explain why these harms concentrate at events outside clinics, where the fixed dose, screening and controlled setting of a clinical protocol are absent.
  • 3.1 Ibogaine and noribogaine inhibit the hERG potassium channel, lengthening the QT interval and raising the risk of torsades de pointes, and noribogaine's half-life of 28 to 49 hours lets the risk outlast the experience by days. The QTc corrects the QT interval for heart rate: Bazett's formula divides by the square root of the RR interval and Fridericia's by the cube root, and the two can place one tracing on either side of a threshold. Most of the 19 deaths reviewed from 1990 to 2008 involved pre-existing heart disease or other drugs.
  • 4.1 Drugs that activate 5-HT2B receptors have caused valvular heart disease, MDMA and MDA make human valve cells proliferate in culture, and one small study found abnormal valves in 8 of 29 people with a history of MDMA use. Trials give one to three doses and a 2023 review found no study designed to test the risk with repeated classic psychedelic dosing, so the question matters most for microdosing, frequent maintenance sessions and heavy MDMA use.
  • 4.2 Ketamine-associated ulcerative cystitis, described in people in Toronto who used ketamine daily, is an inflammation that strips the bladder lining. Urinary symptoms rose with both dose and frequency of use and often improved after stopping, while medical regimens use lower and less frequent doses and esketamine studies found no esketamine-related interstitial cystitis.

Reflection

A hypothetical retreat outside Canada advertises ibogaine sessions "monitored by experienced facilitators" using a pulse oximeter and an automatic blood pressure cuff, with guests free to leave the next morning. Section 1 reported that ibogaine and its metabolite noribogaine inhibit the hERG potassium channel in cell studies; that noribogaine has a half-life of 28 to 49 hours; that in a 2022 Dutch hospital study of 14 people with opioid use disorder, half exceeded a QTc of 500 ms and 6 stayed above 450 ms more than 24 hours after the dose; and that in a 2012 review of 19 deaths between 1990 and 2008, most of those with adequate post-mortem data involved cardiovascular disease or other drugs. Using this evidence, explain why the advertised monitoring is inadequate and describe what a safer protocol would require.

Model answerThe advertised monitoring measures oxygen saturation and blood pressure, but the main danger of ibogaine is electrical: by inhibiting hERG channels, ibogaine and noribogaine slow repolarization and lengthen the QT interval, raising the risk of torsades de pointes. Neither a pulse oximeter nor a blood pressure cuff can detect a long QT interval, which requires an ECG. The timing is also wrong. Noribogaine's half-life of 28 to 49 hours means the risk outlasts the acute experience, and in the Dutch study six of 14 participants still had a QTc above 450 ms beyond 24 hours, so releasing guests the next morning would send some home while still at risk. A safer protocol would begin with screening: a baseline ECG with exclusion of people whose QTc exceeds about 450 ms (men) or 470 ms (women), blood tests for potassium and liver and kidney function, and a review of QT-prolonging medicines and other drug use, since comorbid heart disease and other substances contributed to most of the deaths Alper and colleagues reviewed, although a 2026 review notes arrhythmias in people without known heart disease, so screening alone does not remove the risk. During treatment, it would require repeated ECGs for at least 24 hours, continued while the QTc remains prolonged and ideally with continuous cardiac monitoring, a physician able to give magnesium above 500 ms and a plan for transfer to coronary care. The hospital study observed no torsades de pointes under similar conditions, although its authors note that their intermittent ECGs could have missed brief episodes.

Minimum 20 characters required.

✓ Reflection saved
Knowledge Check: this section

Question 1: In the pooled analysis of 536 psilocybin sessions at Johns Hopkins (Nayak et al., 2026, preprint), when did systolic blood pressure typically peak?

The pooled data showed a peak about 90 minutes after dosing and a return close to baseline by 300 minutes. The 40-minute peak belongs to esketamine, which is why a monitoring schedule suited to one drug can miss the peak of another.

Question 2: Which combination of effects did Campbell and Rosner (2008) describe as a "perfect storm" behind MDMA-associated hyponatremia?

MDMA releases arginine vasopressin, which makes the kidneys retain water, and increases thirst, while fluids are easy to obtain at events, so the blood is diluted. Muscle breakdown (rhabdomyolysis) is a cause of kidney injury, a separate and less common complication.

Question 3: A hypothetical ECG shows a QT interval of 400 ms at a heart rate of 75 beats per minute. What is the QTc by Bazett's formula?

RR = 60 ÷ 75 = 0.8 s, and Bazett's QTc = 400 ÷ √0.8 = 400 ÷ 0.894 = 447 ms. The value of 431 ms is Fridericia's correction (cube root), which illustrates how the two formulas diverge as heart rate rises above 60.

Question 4: Which piece of evidence on 5-HT2B receptors and valvular heart disease comes from a study of people?

Droogmans et al. (2007) examined people with blinded echocardiography and found abnormal valves in 28 percent of people with a history of MDMA use and in none of the controls. The receptor screening, cell culture and binding studies are laboratory evidence, which can show a mechanism but cannot show disease in a living heart.
Section 2 of 5

Psychiatric Risks: Psychosis, Mania, Suicidality, HPPD and Extended Difficulties

⏱ Estimated reading time: 40 minutes
Section 2 of 5

Psychiatric Risks

Psychosis, mania, suicidality, HPPD and extended difficulties.

Two windows

What each kind of study can show

Clinical trials

Screened people, known doses, careful measurement; too small and selective for rare harms.

Population and survey studies

Everyday use and excluded groups; cause is hard to separate from confounding.

Psychosis and mania

Uncommon in trials, raised after severe reactions

<1%Pooled incidence of psychosis in trials, from few and mostly low-quality studies (Sabé et al., 2025)
3.53Adjusted hazard ratio for schizophrenia spectrum disorder after a hallucinogen emergency visit in Ontario (Myran et al., 2025a)

A companion Ontario study found a raised risk of mania (Myran et al., 2025b). Both captured only reactions that needed acute care.

Family history

Who is most vulnerable

  • Safety guidelines exclude first- and second-degree relatives of people with psychotic or bipolar disorders (Johnson et al., 2008).
  • A 2026 review linked manic symptoms to bipolar I disorder, family vulnerability and unsupervised use (Eskinazi et al., 2026).
  • Stratified assessment of family history has been proposed (Downey et al., 2024).
Suicidality in trials

A signal that calls for vigilance

Pooled trials

Suicidality fell on average across seven trials; increases were uncommon (Zeifman et al., 2022).

One phase 2b trial

Suicidal behaviour in 3 participants given 25 mg (Goodwin et al., 2022), at least a month after dosing in people who had not responded (Compass Pathways, 2021).

Phase 3

Company-reported as of October 2026: no clinically meaningful imbalance (Compass Pathways, 2025).

Sizing the signal

Risk difference and number needed to harm

Equation 6.2
\[ \mathrm{RD} = \frac{a}{n_1} - \frac{b}{n_2} \qquad \mathrm{NNH} = \frac{1}{\mathrm{RD}} \]

Worked example with the sponsor's counts (Compass Pathways, 2021): 7/79 versus 4/79 gives RD = 3.8 points (95% CI −4.7 to 12.7) and NNH = 27.

Lasting harms

HPPD, extended difficulties and the rule of three

HPPD

Genuine but uncommon (Halpern & Pope, 2003); no cases reported in contemporary research settings (Hinkle et al., 2024).

Extended difficulties

Over a year for about one third of 608 people who reported them in one survey (Evans et al., 2023).

Zero events in n people allows a true risk of up to about 3/n.

Carry forward

Real, uneven and concentrated risks

  • Serious psychiatric events are uncommon in screened trials, and they do occur (Hinkle et al., 2024).
  • Small trials cannot rule out moderate harms.
  • Section 3 examines screening and fair access.

Content note

This section discusses suicidal ideation, suicidal behaviour and self-injury reported in clinical trials and surveys, and lasting psychological distress after psychedelic use. Support is available at any time from the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8) and, for Indigenous people across Canada, the Hope for Wellness Help Line (1-855-242-3310).

Introduction

Psychedelic-assisted therapy acts on the mind, so its most important risks are psychological. Lesson 5 described challenging experiences during sessions and how people make meaning of them. This section concerns psychiatric harms that are serious or that outlast the session: psychosis and mania, suicidal thoughts and behaviour, persisting perceptual disturbances and extended difficulties.

Learning Objectives

  • 5.1 Summarize the evidence on psychosis and mania after psychedelic use, including the evidence on personal and family history, and explain what each study design can and cannot show.
  • 5.2 Describe the suicidality findings of the COMP360 psilocybin trials and of other psychedelic trials.
  • 5.3 Define hallucinogen persisting perception disorder and state what is known about how often and for how long it occurs.
  • 5.4 Define extended difficulties and state what is known about how often and for how long they occur.
  • 5.5 Write a precise summary of psychiatric risk that distinguishes what trials have observed from what they are too small or too selective to detect.
  • 6.1 Calculate a risk difference, a relative risk and a number needed to harm from published counts, and interpret their confidence intervals.

Concern about these harms is old. Johnson, Richards and Griffiths (2008) summarize a 1960 survey by the psychiatrist Sidney Cohen of researchers who had given LSD or mescaline to research participants and patients. Among about 1,200 research participants who were not patients, one psychotic reaction lasted more than 48 hours (0.8 per 1,000) and no suicide attempts occurred; among patients, prolonged psychotic reactions occurred at 1.8 per 1,000, suicide attempts at 1.2 per 1,000 and suicides at 0.4 per 1,000. Only 44 of the 62 researchers returned the survey, so these rates are uncertain. In a 2024 meta-analysis of modern studies, about 4 percent of trial participants with neuropsychiatric conditions had a serious adverse event, including worsening depression, suicidal behaviour, psychosis and convulsive episodes, and no deaths by suicide, persistent psychotic disorders or cases of hallucinogen persisting perception disorder were reported in contemporary research settings (Hinkle et al., 2024). The evidence arrives through two windows, compared in Figure 6.4.

Clinical trials Population and survey studies Who: screened, prepared participants Exposure: known dose, supported setting Size: tens to hundreds of people Follow-up: weeks to months Can show common harms, measured carefully Cannot show rare harms, or harms in excluded groups Who: people using in ordinary life Exposure: unknown dose and setting Size: thousands to millions of people Follow-up: varies, often self-report Can show rare harms and harms in excluded groups Cannot show cause apart from confounding or selection
Figure 6.4. Two windows on psychiatric risk: what clinical trials and population or survey studies can and cannot show about harms after psychedelic use.

Neither window shows the whole picture, so each body of evidence below is read through both.

5.1 Psychosis and Mania

Psychosis is a state in which a person loses contact with shared reality, through hallucinations, delusions or disorganized thinking. Mania is a period of abnormally elevated or irritable mood with increased energy, reduced need for sleep and impaired judgement, and it defines bipolar I disorder. The concern is that in a vulnerable person, a psychedelic could trigger an episode that persists after the drug has gone. Johnson, Richards and Griffiths (2008) therefore recommend excluding anyone with a current or past psychotic disorder or bipolar I or II disorder, and anyone with a first- or second-degree relative with these disorders. Reviews suggest that psychosis is uncommon in research settings: a 2025 meta-analysis estimated its incidence at 0.2 percent in uncontrolled trials and 0.6 percent in randomized trials, from mostly low-quality studies (Sabé et al., 2025), and a 2026 systematic review found that manic symptoms after psychedelics were typically brief and self-limited, with higher risks reported in people with bipolar I disorder, a family vulnerability, polysubstance use or unsupervised use (Eskinazi et al., 2026). Because this evidence comes mainly from observational studies and small trials, research on these risks is evolving.

5.1.1 Evidence from Ontario Health Records

Two Canadian cohort studies used the health records of everyone insured in Ontario. Among 9,244,292 people aged 14 to 65 with no history of psychosis, 5,217 had an emergency department visit coded as involving hallucinogen use; within three years, 3.99 percent of them were diagnosed with a schizophrenia spectrum disorder, compared with 0.15 percent of the general population. Adjusted only for age and sex, the hazard ratio was 21.32 (95 percent confidence interval 18.58 to 24.47); after further adjustment for other substance use and mental health conditions, it was 3.53 (3.05 to 4.09), and the risk was also higher than after emergency visits involving alcohol (hazard ratio 4.66) or cannabis (1.47) (Myran et al., 2025a). A second study found that within three years of acute care involving hallucinogens, 1.43 percent of people had an episode of mania requiring acute care, compared with 0.06 percent of a matched group, a weighted hazard ratio of 5.97 (3.29 to 10.82) (Myran et al., 2025b). An emergency visit marks a severe reaction, so these people are a small minority of those who use hallucinogens, and the authors state that the results may not generalize to people who never need acute care. Some visits may also reflect the first signs of an illness already developing.

5.1.2 Evidence from Twin and Survey Studies

In 16,255 Swedish adolescent twins, psychedelic use was associated with fewer psychotic symptoms after adjustment for other drug use, but its association with manic symptoms depended on genetic vulnerability to schizophrenia or bipolar I disorder (Simonsson et al., 2024). In a longitudinal survey of adults in the United States with 12,345 followed up, psychedelic use was associated with increases in psychotic and manic symptoms only when it occurred in an illegal context, and the increase in manic symptoms was moderated by a personal history of schizophrenia or bipolar I disorder (Simonsson et al., 2025). A cross-sectional survey of 548 people found no association between lifetime use and psychotic symptoms after adjustment, including among those with a personal or family history of psychotic or bipolar disorders (Dourron et al., 2025).

5.1.3 Bipolar Disorder

In a web survey of 541 people with self-reported bipolar disorder who had used psilocybin, 32.2 percent described new or increased symptoms afterwards, most prominently manic symptoms, poor sleep and anxiety, and 3.3 percent had used emergency services (Morton et al., 2023). An open-label trial of a single 25 mg dose in bipolar II depression enrolled 19 of 70 people approached, and among the 15 reported, mania scores did not change significantly (Aaronson et al., 2024). Downey and colleagues (2024) argue that a family history of bipolar disorder should prompt stratified assessment, weighing how closely related the relative is, the type of bipolar disorder, the relative's age at onset and the participant's age, and they oppose blanket exclusion. Table 6.3 brings these studies together.

Table 6.3. Key studies of psychosis and mania after psychedelic use, with the main limitation of each.

StudyDesignMain findingMain limitation
Myran et al. (2025a, 2025b)Ontario cohorts, over 9 million peopleMore psychotic and manic disorders after hallucinogen acute careSevere reactions only; possible reverse causation
Simonsson et al. (2024)Swedish adolescent twinsManic symptoms depended on genetic vulnerabilitySelf-report at one age
Simonsson et al. (2025)Longitudinal online surveyIncreases only with use in illegal contextsPurposive sample; 56 percent retention
Morton et al. (2023)Survey of people with bipolar disorderOne third reported new or increased symptomsSelf-selected; self-reported diagnosis
Aaronson et al. (2024)Open-label trial, bipolar II depressionNo significant change in mania scoresFifteen participants; no control group

Taken together, the studies and reviews in this section support caution for people with a personal history of psychotic or bipolar I disorder. Downey and colleagues (2024) note that evidence on family history comes mainly from case studies and surveys, which leaves open how much a family history adds once a person has been screened and supported, a question Section 3 returns to.

5.2 Suicidality Signals in Trials

Depression carries a risk of suicide whatever the treatment, so trials must separate what a treatment causes from what the illness brings. The box below defines the terms that trial reports use.

How trials describe suicidality

Suicidal ideation means thoughts of ending one's life, from a passive wish to be dead to an active plan; suicidal behaviour includes preparatory acts and attempts; intentional self-injury is deliberate self-harm with or without suicidal intent.

A treatment-emergent adverse event begins or worsens after treatment starts, whether or not the treatment caused it, and a serious adverse event is life-threatening, fatal or requires hospitalization. Trials measure suicidality with the Columbia Suicide Severity Rating Scale (C-SSRS), and an independent data and safety monitoring board reviews unblinded safety data while a trial runs.

5.2.1 The COMP360 Phase 2b Trial

Goodwin and colleagues (2022) randomly assigned 233 adults with treatment-resistant depression to a single dose of COMP360 psilocybin at 25 mg, 10 mg or 1 mg (the control), with psychological support, after antidepressants had been stopped at least two weeks before baseline; people at clinically significant risk of suicide were excluded. Adverse events occurred in 77 percent of participants, and suicidal ideation or behaviour or self-injury occurred in all dose groups (Table 6.4).

Table 6.4. Suicidality in the COMP360 phase 2b trial by dose group (Goodwin et al., 2022; company-reported rows from Compass Pathways, 2021).

Measure25 mg10 mg1 mg
Participants randomized797579
Suicidal ideation at baseline21 (27%)27 (36%)19 (24%)
Worsening of suicidal state, baseline to week 311 (14%)13 (17%)7 (9%)
Any suicidality adverse event (company-reported)764
Serious suicidality adverse event (company-reported)441
Serious events after week 3Suicidal behaviour (3)Self-injury, depression, suicidal ideation (1 each)Self-injury (1)

The sponsor's analysis, released in December 2021, reported that all participants with these events had described suicidal thoughts before the trial, that most serious events occurred at least a week after the session, and that all suicidal behaviours occurred at least a month after it, in people who had not responded (Compass Pathways, 2021). The trial authors concluded that suicidality "demands clinical vigilance in future trials of psilocybin for depression" (Goodwin et al., 2022), and Mann (2023) called for future research to evaluate psilocybin's safety in terms of suicide risk.

5.2.2 Later and Other Trials

Two phase 3 trials of COMP360 have reported topline results only through company announcements (as of October 2026). For COMP005, which compared a single 25 mg dose with placebo in 258 participants, the company quoted its monitoring board as finding "no evidence of a clinically meaningful imbalance between treatment arms in suicidality" in either phase 3 study (Compass Pathways, 2025). For COMP006, with 581 participants, the company reported serious suicidal ideation in under 1 percent across both trials and one serious suicidal behaviour event, in the 1 mg group (Compass Pathways, 2026). Few counts by group were given, so these statements remain company-reported until the data are published. Elsewhere, a meta-analysis of individual data from seven trials found large decreases in suicidality from baseline, with acute and post-acute increases in 6.5 and 3.0 percent of participants (Zeifman et al., 2022). An open-label study of COMP360 given with an SSRI found no increase in suicidal ideation or behaviour among 19 participants (Goodwin et al., 2023). In a 2021 phase 3 trial of MDMA-assisted therapy, suicidality events of special interest occurred in 3 of 46 participants given MDMA and 5 of 44 given placebo, which the authors judged were not induced by MDMA (Mitchell et al., 2021), although Lesson 9 describes the FDA advisory committee's 2024 concern that adverse events in that program were under-recorded.

Counts of events cannot show what such an event is like for the person who has it. Case 6.2 shows a suicidality adverse event from the inside.

Case 6.2: A participant's account of a prolonged adverse event

Wahba and colleagues (2024) described a participant in a phase 2b trial of psilocybin for treatment-resistant depression whose suicidal ideation increased after dosing and who had a prolonged period of severely restricted eating that led to destabilization and a need for support, while her depression scores improved little. In a written account, she described the experience as helpful overall and said it led to changes in her life that she valued. The authors concluded that psilocybin can lead to temporary worsening of suicidal ideation and to adverse events that outlast its acute effects, and called for qualitative study of serious adverse events alongside trials.

5.3 Hallucinogen Persisting Perception Disorder

Hallucinogen persisting perception disorder (HPPD) is the re-experiencing, after use has stopped, of perceptual distortions first experienced while intoxicated, to a degree that causes distress or impairment (Halpern, Lerner & Passie, 2018). Halpern and Pope (2003) analyzed 20 studies published between 1955 and 2001 and concluded that HPPD appears to be a genuine but uncommon disorder, sometimes persisting for months or years, reported most often after illicit LSD use and less often after LSD given in research or treatment. A later review distinguishes Type 1, brief "flashbacks", from Type 2, a chronic form that waxes and wanes, and links it consistently with dissociative symptoms and anxiety (Halpern et al., 2018). Johnson and colleagues (2008) described its incidence as unknown and advised researchers to ask about perceptual disturbances at follow-up, Halpern and Pope (2003) called for further studies of its prevalence, and a 2024 meta-analysis found no cases reported in contemporary research settings (Hinkle et al., 2024).

5.4 Extended Difficulties

Some people describe difficulties lasting weeks, months or years after a psychedelic experience without meeting the criteria for a specific disorder; researchers call these extended difficulties. Evans and colleagues (2023) collected accounts from 608 people who reported them. The most common forms were anxiety and fear, existential struggle, social disconnection, depersonalization (feeling detached from oneself) and derealization (feeling that the world is unreal). For about one third the difficulties lasted more than a year, and for about one sixth more than three years. Knowing the dose and drug and having a less difficult acute experience predicted shorter difficulties, and a guided setting predicted a narrower range. In a survey of 1,993 people about their single most difficult experience with psilocybin mushrooms, which respondents called their worst "bad trip", 11 percent said they had put themselves or others at risk of harm and, of those whose experience was more than a year earlier, 7.6 percent had sought treatment for enduring symptoms; three cases appeared associated with enduring psychotic symptoms and three with attempted suicide, while 84 percent reported benefiting (Carbonaro et al., 2016). The accordion summarizes what such surveys can establish.

What the surveys establishv

Extended difficulties exist, can last for years and take recognizable forms, and knowledge of the drug, a less difficult acute experience and a guided setting are associated with milder courses (Evans et al., 2023). Risky behaviour was associated with higher estimated dose and the absence of physical comfort and social support (Carbonaro et al., 2016).

What the surveys cannot establishv

Self-selected samples cannot give incidence, since people with very distressing experiences may be more likely to respond, and associations with setting may reflect differences between the people who choose guided and unguided use. Trials follow every participant, as Case 6.2 shows, but their samples are small and their follow-up rarely exceeds a few months.

5.5 Stating Psychiatric Risk Precisely

Statements about psychedelic safety often compress this evidence, and some claim more than it supports. A claim that no serious adverse events occur in screened participants conflicts with the roughly 4 percent of patient participants who had one in pooled data (Hinkle et al., 2024) and with the suicidal behaviour in the COMP360 phase 2b trial. A claim that psychedelics cause psychosis in the general population goes beyond the Ontario cohorts, whose authors limit their conclusions to people who needed acute care. The absence of a reported harm also needs care, as the box below explains.

When nothing goes wrong

If a study of n people observes no cases of an event, the upper limit of the 95 percent confidence interval for the true risk is approximately 3 ÷ n for samples above about 30, the rule of three (Eypasch et al., 1995). A trial of 233 participants with no cases of an event is still compatible with a true risk of up to 3 ÷ 233, about 1.3 percent. Across the 3,504 participants pooled by Hinkle and colleagues (2024), the bound for HPPD would be about 0.09 percent, but only if every study had looked for it, and fewer than a quarter of recent studies assessed adverse events systematically.

A precise summary, as of October 2026, would say that serious psychiatric adverse events are uncommon in screened trial participants but occur in about 4 percent of patients in pooled data; that suicidal ideation and behaviour have occurred after psilocybin in depression trials, with an imbalance in one phase 2b trial that company-reported phase 3 data have not shown; that people with severe reactions outside clinics have higher later rates of psychotic and manic disorders; and that extended difficulties lasting a year or more occur at a frequency that surveys of self-selected samples cannot establish. Try it 6.2 asks you to apply this standard to a clinic's claim.

Try it 6.2: Correcting a safety claim

A hypothetical clinic's website states: "Psychedelic therapy has no serious psychiatric side effects. Trials have never recorded a case of psychosis, suicide or lasting harm." Write three sentences that correct the statement, each citing a source, and one sentence that states what remains unknown.

Suggested answer: In pooled data from 114 studies, about 4 percent of participants with neuropsychiatric conditions had a serious adverse event, including suicidal behaviour and psychosis (Hinkle et al., 2024). In the COMP360 phase 2b trial, three participants in the 25 mg group reported suicidal behaviour after week 3 (Goodwin et al., 2022). Prolonged adverse events have been described in trial participants (Wahba et al., 2024). The frequency of rare harms in people whom trials exclude, such as people with a family history of bipolar disorder, remains unknown.

6.1 Interpreting the Suicidality Signal

Several explanations remain open for the imbalance in suicidality adverse events in the COMP360 phase 2b trial. With fewer than 80 people per group, a difference of a few participants can arise by chance. The population had high baseline suicidality, and the timing, weeks after dosing among people who had not responded, is consistent with the course of severe depression after a treatment that did not help. All participants had stopped antidepressants, so discontinuation could have contributed to events in every group, although it cannot explain a difference between randomized groups. Equation 6.2 gives the measures for sizing such a difference.

Risk difference, relative risk and number needed to harm
RD = a⁄n1 − b⁄n2;   RR = (a⁄n1) ÷ (b⁄n2);   NNH = 1 ÷ RDEq 6.2
The risk difference is the proportion with the event in the treated group (a events among n1 people) minus the proportion in the comparison group (b events among n2 people). The relative risk is the ratio of the two proportions. The number needed to harm is the reciprocal of a positive risk difference: the number of people who would need to receive the treatment for one additional person to have the event.

Worked Example 6.2. The sponsor reported a suicidality adverse event in 7 of 79 participants given 25 mg and 4 of 79 given 1 mg. The risks are 8.9 and 5.1 percent, the risk difference is 3.8 percentage points and the relative risk is 1.75. The number needed to harm is 1 ÷ 0.038 = 26.3, rounded up to 27. The 95 percent confidence interval for the risk difference (Newcombe's method) runs from −4.7 to 12.7 percentage points, and for the relative risk from 0.53 to 5.74, so the data are compatible with no difference, a small reduction or a substantial increase. Use Calculator 6.2 to repeat the calculation for serious events and for the Ontario cohort.

With fewer than 100 people per group, a trial cannot distinguish a moderate increase in risk from none, which is why full publication of the phase 3 data matters.

Psychiatric risks are real and uneven. The 2024 meta-analysis by Hinkle and colleagues (2024) found classic psychedelics generally well tolerated in research settings, although serious adverse events did occur, and the studies and reviews in this section point to risks concentrated in identifiable groups: people with a personal history of psychotic or bipolar I disorder, people with severe depression who do not respond, and people who use psychedelics in unsupported settings. Section 3 examines how screening decisions try to protect these groups and whom they may exclude unfairly.

Key Takeaways

  • 5.1 Ontario cohorts found higher later rates of schizophrenia spectrum disorders (adjusted hazard ratio 3.53) and mania (weighted hazard ratio 5.97) after acute care involving hallucinogens, but they describe only people with severe reactions. Twin and survey studies point to genetic vulnerability, a personal history of psychotic or bipolar I disorder and use in illegal contexts as moderators, and trials exclude the people at highest risk, so each design shows only part of the picture.
  • 5.2 In the COMP360 phase 2b trial, suicidal ideation, behaviour or self-injury occurred in all dose groups, and the three suicidal behaviours in the 25 mg group occurred at least a month after dosing in people who had not responded. Company-reported phase 3 statements describe no clinically meaningful imbalance, and pooled data from seven trials show large average decreases in suicidality, so the signal calls for clinical vigilance rather than a settled conclusion.
  • 5.3 Hallucinogen persisting perception disorder is the distressing re-experiencing of perceptual distortions after use has stopped. It appears to be genuine but uncommon, has been reported most often after illicit LSD use and can persist for months or years, and its incidence has not been established; a 2024 meta-analysis found no cases reported in contemporary research settings.
  • 5.4 Extended difficulties, such as anxiety, existential struggle, social disconnection, depersonalization and derealization, lasted more than a year for about one third of 608 people who reported them. Knowing the drug and dose, a less difficult acute experience and a guided setting were associated with milder courses, but self-selected surveys cannot give their frequency among everyone who uses psychedelics.
  • 5.5 A precise statement of psychiatric risk separates what trials have observed from what they are too small or too selective to detect: serious psychiatric events occur in about 4 percent of patients in pooled data, and claims of no serious harm overstate the evidence. When a study of n people observes no cases, the rule of three still allows a true risk of up to about 3 ÷ n, and only if the study looked for the event.
  • 6.1 The risk difference subtracts the proportion with an event in the comparison group from the proportion in the treated group, the relative risk divides the two, and the number needed to harm is the reciprocal of a positive risk difference. For suicidality adverse events in 7 of 79 and 4 of 79 participants, the risk difference is 3.8 percentage points and the number needed to harm 27, but the 95 percent confidence interval of −4.7 to 12.7 points includes zero, so the data are compatible with no difference, a small reduction or a substantial increase.

Reflection

You are drafting a paragraph for a patient information sheet for a hypothetical psilocybin trial in treatment-resistant depression. The facts available are these: in the COMP360 phase 2b trial, a suicidality adverse event occurred in 7 of 79 participants given 25 mg and 4 of 79 given 1 mg (95 percent confidence interval for the difference, −4.7 to 12.7 percentage points); three participants in the 25 mg group reported suicidal behaviour after week 3, all at least a month after dosing and all among people who had not responded; and company-reported phase 3 statements found no clinically meaningful imbalance in suicidality between groups. Write the paragraph so that it neither overstates nor understates the risk, and state what follow-up the evidence implies.

Model answerPeople with treatment-resistant depression often have thoughts of suicide, and these thoughts can continue or return during any treatment. In an earlier trial of the study drug, some participants in every dose group, including the lowest dose, reported suicidal thoughts, self-injury or suicidal behaviour. Slightly more participants given the highest dose reported such events (7 of 79, compared with 4 of 79 at the lowest dose), but the trial was too small to tell whether this difference was caused by the drug or arose by chance. Three people given the highest dose reported suicidal behaviour more than a month after their session, and all three had not improved with treatment. Two larger trials, reported as of October 2026 only by the company that makes the drug, found no meaningful difference in suicidality between groups. Because these events happened weeks after dosing, the study team will meet you the day after your session and check in with you regularly over the following weeks and months, asking each time about your mood and any thoughts of suicide. If your depression does not improve, the team will plan further care with you. Before your session you will build a written safety plan, and you can contact the team or the 9-8-8 Suicide Crisis Helpline at any time.

Minimum 20 characters required.

✓ Reflection saved
Knowledge Check: this section

Question 1: In the Ontario cohort of Myran et al. (2025a), the hazard ratio for a schizophrenia spectrum disorder after a hallucinogen emergency visit fell from 21.32 (age and sex adjusted) to 3.53 after further adjustment. What does this change most directly show?

Adjusting for comorbid substance use and mental health conditions reduced the hazard ratio sharply, so these factors accounted for much of the crude association; a hazard ratio of 3.53 with an interval of 3.05 to 4.09 still indicates elevated risk. Visits involving hallucinogens carried a higher risk than visits involving alcohol (hazard ratio 4.66 in that comparison).

Question 2: The sponsor of the COMP360 phase 2b trial reported a suicidality adverse event in 7 of 79 participants given 25 mg and 4 of 79 given 1 mg. What are the risk difference and the number needed to harm?

The risks are 8.9 and 5.1 percent, a difference of 3.8 percentage points, and 1 ÷ 0.038 = 26.3, rounded up to 27. The figure 1.75 is the relative risk, and the 95 percent confidence interval for the difference (−4.7 to 12.7 points) includes zero.

Question 3: According to the sponsor's analysis of the COMP360 phase 2b trial, when did the suicidal behaviours occur?

The sponsor reported that all suicidal behaviours occurred at least a month after the session and that all participants reporting them were non-responders at their last assessment, which is why follow-up must extend over weeks to months. The trial report placed three suicidal behaviours in the 25 mg group after week 3.

Question 4: A hypothetical trial of 300 participants observes no cases of hallucinogen persisting perception disorder. By the rule of three, what is the approximate upper limit of the 95 percent confidence interval for the true risk?

The rule of three gives an upper limit of about 3 ÷ n, here 3 ÷ 300 = 0.01, or 1 percent (Eypasch et al., 1995). Observing zero cases is compatible with a true risk as high as this bound, so a report of no cases does not establish that the risk is zero.
Section 3 of 5

Screening and Eligibility: Exclusion Criteria, Thresholds, Stabilization and Fair Access

⏱ Estimated reading time: 40 minutes
Section 3 of 5

Screening and Eligibility

Exclusion criteria, thresholds, stabilization and fair access.

The pathway

Three possible decisions

Continue

Proceed to preparation (Lesson 7).

Defer

Stabilize or resolve an issue, then reassess.

Exclude

The person does not meet this protocol's criteria.

Psychiatric criteria

Who is usually excluded

  • A current or past psychotic disorder (Johnson et al., 2008).
  • Bipolar I or II disorder, and close relatives with these disorders.
  • Clinically significant suicide risk (Goodwin et al., 2022).

Criteria vary with the population and the question being studied (Mitchell et al., 2021).

Medical criteria

Thresholds are conventions

Blood pressure

Exclude above 140/90 mmHg (Johnson et al., 2008); a 2026 preprint proposes below 160/100 mmHg for psilocybin (Nayak et al., 2026).

QTc for ibogaine

One hospital study excluded QTc above 450 ms in men and 470 ms in women (Knuijver et al., 2022).

Stabilization and medicines

Timing and tapering

  • Deferral for stabilization is a judgement about timing.
  • Antidepressant withdrawal is common and can mimic relapse (Horowitz & Taylor, 2019).
  • Continuing antidepressants appeared generally safe in early studies (Tap et al., 2025).
Fair access

Who may be excluded unfairly

Narrow samples

85% of participants were non-Hispanic White in pooled data from 39 studies, with some change since 2018 (Hughes & Garcia-Romeu, 2024).

Contested criteria

Some thresholds and family-history rules are being questioned (Downey et al., 2024).

Logistics

Lodging can replace a companion at discharge (Health Canada, 2022).

Carry forward

Screening lowers risk without removing it

  • Deferral and exclusion are different decisions.
  • Some criteria deserve revisiting as evidence grows.
  • Section 4 turns to managing events and aftercare.

Content note

This section discusses suicide risk assessment as part of screening. Support is available at any time from the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8) and, for Indigenous people across Canada, the Hope for Wellness Help Line (1-855-242-3310).

Introduction

Sections 1 and 2 showed that the risks of psychedelics fall most heavily on identifiable groups: people with heart disease, people taking interacting medicines, people with a personal history of psychotic or bipolar disorders and people in acute crisis. Screening is the process of identifying those people before treatment, and it is the first safety step in every protocol. This section describes the criteria in current use, the thresholds behind them, the work of stabilization and medication review, and the people that screening may exclude unfairly.

Learning Objectives

  • 7.1 Describe the psychiatric and medical exclusion criteria used in psychedelic trials and explain the rationale for each.
  • 7.2 Interpret blood pressure and QTc thresholds for eligibility, and evaluate the evidence behind them.
  • 7.3 Explain the purpose of stabilization before treatment and distinguish a deferral from an exclusion.
  • 7.4 Describe how a medication review is carried out, and weigh the risks and benefits of tapering antidepressants before treatment.
  • 7.5 Identify groups who may be excluded unfairly by current criteria, and apply screening criteria to hypothetical referrals.

Screening serves two purposes that do not always align. One is to protect the person, by keeping out anyone for whom the risk clearly outweighs the potential benefit. The other is to protect the validity of a trial, by enrolling a uniform group so that the effect of the treatment can be measured with less noise. A criterion that serves the second purpose may exclude people who could be treated safely. The distinction matters more as treatment moves from trials into practice, which Williams and colleagues (2026) describe as under way in Australia. In Canada, Alberta has required psychedelic drug treatment services to be licensed since 16 January 2023, a requirement its licensing page still described in October 2026 (Government of Alberta, 2022, 2025), and Lesson 11 describes both jurisdictions. Williams and colleagues (2026) reviewed the medical exclusion criteria registered for psychedelic trials, examined the rationale and medical basis of each, traced how they changed over 25 years and discussed which should apply in hospital practice. In Canada, Health Canada's expectations for clinical trials of psychedelic-assisted psychotherapy, published on 5 December 2022, state that a licensed physician should be involved in screening potential participants (Health Canada, 2022). Figure 6.5 shows the steps of a typical screening pathway.

Referralreason and goals History andexamination TestsECG, blood work Medication andsubstance review Continue topreparation (Lesson 7) Defer and stabilize,then reassess Exclude underthe criteria Decision, with specialist input where needed dashed line: a deferral returns to reassessment
Figure 6.5. A typical screening pathway for psychedelic-assisted therapy, ending in one of three decisions; a deferral returns the person to reassessment once the issue that prompted it has been resolved.

The pathway has three outcomes, and the difference between the last two is important. An exclusion means that the person does not meet the criteria of a particular protocol. A deferral means that something can change, such as blood pressure, a crisis or a medication, and that the person will be reassessed. The rest of this section examines each step in turn, beginning with the psychiatric criteria.

7.1 Psychiatric and Medical Exclusion Criteria

7.1.1 Psychiatric Criteria

The psychiatric criteria follow directly from the evidence in Section 2. Johnson, Richards and Griffiths (2008) recommend excluding people with a current or past psychotic disorder, other than one induced by a substance or a medical condition, people with bipolar I or II disorder, and people with a first- or second-degree relative with these disorders. In studies of healthy volunteers they also exclude people with current or recent (within five years) alcohol or drug dependence, current major depression and several other current disorders. Recent trials in patient populations have adapted these rules to their own questions, and Table 6.5 lists the main criteria with the rationale for each.

Table 6.5. Common psychiatric exclusion criteria in psychedelic research, with the rationale for each and examples of sources that apply or question it.

CriterionRationaleExamples
Current or past psychotic disorderRisk of a persistent psychotic episode (Section 2)Johnson et al. (2008); Knuijver et al. (2022) excluded any history of psychotic symptoms
Psychotic features in the current depressive episodeOverlap with psychosis riskGoodwin et al. (2022) enrolled only major depression without psychotic features
Bipolar I or II disorderRisk of maniaJohnson et al. (2008); Aaronson et al. (2024) deliberately tested bipolar II depression
A first- or second-degree relative with a psychotic or bipolar disorderInherited vulnerabilityJohnson et al. (2008); Downey et al. (2024) propose stratified assessment
Clinically significant suicide riskSafety during and after treatmentGoodwin et al. (2022); Knuijver et al. (2022) excluded suicidality and severe major depression
Current or recent substance dependenceSafety and interpretability in healthy-volunteer studiesJohnson et al. (2008); a 2021 MDMA phase 3 trial included people with a history of alcohol and substance use disorders (Mitchell et al., 2021)

The table shows that criteria vary with the population and the question. A trial of MDMA-assisted therapy for severe post-traumatic stress disorder enrolled people with dissociation, depression, histories of alcohol and substance use disorders and childhood trauma, because these are common comorbidities of the disorder being treated (Mitchell et al., 2021). A study of ibogaine for opioid use disorder necessarily enrolled people who use opioids, and it excluded people with a history of psychotic symptoms, severe major depression or suicidality (Knuijver et al., 2022). The family-history criterion is contested (Downey et al., 2024), since it excludes many people who have never been ill, and Section 2 showed that the evidence on how much it adds to risk comes mainly from case studies, surveys and observational studies. Medical criteria are examined next.

7.1.2 Medical Criteria

Medical screening aims to find conditions that the drug's physical effects could worsen. Johnson, Richards and Griffiths (2008) recommend establishing good general health through a medical history, a physical examination, a 12-lead ECG, blood chemistry, hematology and urinalysis, and excluding people who are pregnant or not using effective contraception. Their blood pressure criterion excluded people whose resting blood pressure exceeded 140/90 mmHg, averaged across four assessments on at least two separate days. Drug-specific criteria follow from Section 1. The ibogaine study in Case 6.1 excluded people with a QTc above 450 ms (men) or 470 ms (women), abnormal potassium, severe liver or kidney disease and medicines that prolong the QT interval, with an exception for methadone, which participants were taking at screening and which was replaced with morphine for eight days before dosing (Knuijver et al., 2022).

7.2 Cardiovascular Thresholds and Where They Come From

Thresholds such as 140/90 mmHg are conventions chosen to be cautious, and they can be tested against data. The pooled analysis of 536 psilocybin sessions described in Section 1 argues that the 140/90 criterion was set conservatively without strong empirical support (Nayak et al., 2026). In those data, higher baseline blood pressure was associated with smaller increases after psilocybin, which the authors interpret as a ceiling effect, and they recommend broadening eligibility to blood pressure below 160/100 mmHg while continuing to exclude people with established cardiovascular disease. As of October 2026, the analysis was a preprint from a single research centre, so its recommendation awaits peer review and replication. Table 6.6 brings together the cardiovascular thresholds discussed in this lesson.

Table 6.6. Cardiovascular and ECG thresholds used for eligibility and during sessions, by source.

SourceMeasureThreshold and its use
Johnson et al. (2008)Resting blood pressureExclude above 140/90 mmHg, averaged across four readings on two days; antihypertensive medicine available during sessions
Nayak et al. (2026, preprint)Resting blood pressureProposes eligibility below 160/100 mmHg for psilocybin, with established cardiovascular disease still excluded
Esketamine prescribing information (Janssen, 2026)Blood pressure before and after each doseWeigh the risk above about 140/90 mmHg; reassess at about 40 minutes; monitor for at least 2 hours
Knuijver et al. (2022)QTc (correction not stated for the screening limits; Fridericia during monitoring)Exclude above 450 ms (men) or 470 ms (women); give magnesium during monitoring above 500 ms
Drew et al. (2010)QTc during drug treatmentAbove 500 ms is highly abnormal; a value above 500 ms or an increase of 60 ms or more calls for prompt action

The box below sets out how to read thresholds such as these.

Reading a threshold

A threshold divides a continuous measure into two groups, so people just above and just below it differ very little. A strict threshold reduces the chance of enrolling someone at risk and increases the number of people turned away who could have been treated safely; a permissive threshold does the reverse.

Judging a threshold involves three questions: what harm it is meant to prevent, what evidence links the measure to that harm in the population being treated, and what happens to the people it excludes. For blood pressure, Table 6.6 shows that the answers differ by drug, because esketamine, psilocybin and ibogaine affect the cardiovascular system in different ways and over different times.

Medical criteria, like psychiatric ones, separate people who are ready for treatment now from those who are not. Some conditions can change, and the next part of this section concerns the work of helping a person reach a state in which treatment is safe.

7.3 Stabilization and Suicide Risk Assessment

Stabilization is the process of treating or resolving an acute problem before psychedelic treatment begins. Typical reasons for deferral include a current crisis, uncontrolled blood pressure, and withdrawal from alcohol or benzodiazepines, which Alper, Stajić and Gill (2012) identified as a risk factor for seizures in deaths associated with ibogaine. Active suicidal intent or a recent suicide attempt is different: it makes the person ineligible at this time and calls for an immediate safety assessment and referral to crisis care. Trials have also selected people whose lives were stable enough to manage an intense experience and its aftermath: the ibogaine study in Case 6.1 enrolled people with a stable psychosocial situation, and its authors list this selection among the study's limitations (Knuijver et al., 2022).

Suicide risk assessment is a structured part of screening. Trials use the Columbia Suicide Severity Rating Scale, which asks about the presence, intensity and history of suicidal thoughts and behaviour, and the trial of psilocybin in bipolar II depression repeated it at every visit (Aaronson et al., 2024). The COMP360 phase 2b trial excluded people judged to be at clinically significant risk of suicide, so its results may not apply to people at high risk (Goodwin et al., 2022). This is the central tension of screening in depression: the people with the most severe illness may stand to gain, and they are also the people for whom an adverse turn after treatment would be most dangerous. Section 2 showed that suicidal behaviour in the phase 2b trial occurred weeks after dosing, which is why Health Canada (2022) expects check-in visits in the days and weeks after administration, and why Section 4 treats follow-up as part of safety.

When the concern is active suicidal intent or a recent attempt, the person is ineligible at this time and needs an immediate safety assessment and referral to crisis care, such as the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8); any later reassessment for psychedelic treatment would follow only after that care. Lesson 7 describes the safety plans that are built during preparation, and Section 4 of this lesson describes follow-up after dosing.

7.4 Medication Review and Tapering

A medication review records everything a person takes, including prescribed medicines, over-the-counter products, herbal preparations and non-prescribed substances, and checks each for interactions with the planned drug. Lesson 3 explains the pharmacology of these interactions, and the flip cards below summarize the categories a review must cover, drawing on the interactions listed by Johnson, Richards and Griffiths (2008) and the other sources cited.

Serotonergic antidepressantsClick to explore
LithiumClick to explore
Monoamine oxidase inhibitors and herbal productsClick to explore
Drugs that prolong the QT intervalClick to explore

Because serotonergic antidepressants may alter the psychedelic effect, a washout, in which the antidepressant is tapered and stopped before dosing, has been a common requirement for joining psilocybin trials (Goodwin et al., 2023), and a 2025 scoping review notes that protocols often require stopping antidepressants at least two weeks before dosing (Tap et al., 2025). In the COMP360 phase 2b trial, antidepressants were tapered and stopped at least two weeks before the baseline visit, and participants were asked to remain off them for the first three weeks after dosing (Goodwin et al., 2022); the trial in bipolar II depression stopped psychotropic medicines at least two weeks before dosing (Aaronson et al., 2024). Stopping an antidepressant carries its own risks. Horowitz and Taylor (2019) report that withdrawal syndromes occur often after stopping SSRIs, can be severe and can be mistaken for a return of depression. They note that guidelines recommend tapers of two to four weeks, while tapers over months to much lower doses have been more successful in reducing withdrawal symptoms.

The alternative is to give psilocybin alongside the antidepressant. In an open-label study, 19 participants with treatment-resistant depression received 25 mg of COMP360 while continuing an SSRI; 8 (42.1 percent) met criteria for response and remission at week 3, and there were no serious treatment-emergent adverse events (Goodwin et al., 2023). The study was small and uncontrolled, and its authors call for larger comparator-controlled trials. A 2025 scoping review of 18 studies found the combination of antidepressants and classic psychedelics generally safe and tolerable, with no increased risk of serotonin syndrome, particularly for psilocybin; its authors conclude that antidepressants can be maintained and call for randomized placebo-controlled trials (Tap et al., 2025). This evidence comes mainly from early studies, and research on it is evolving. In practice, any decision to taper belongs to the person and their prescriber, made with an honest account of what is known about both paths. Try it 6.3 applies these points to a hypothetical medication list.

Try it 6.3: Reviewing a medication list

A hypothetical person referred for psilocybin-assisted therapy reports taking sertraline (an SSRI) for depression, an antihistamine for allergies, St. John's wort bought at a health food store and occasional cannabis. Using the flip cards and the tapering evidence above, list the questions the screening team would raise about each item and say who should be involved in each decision.

Suggested answer: For sertraline, the team would ask whether the protocol requires a taper; if it does, the prescriber should plan the taper, allowing for withdrawal symptoms that can resemble relapse (Horowitz & Taylor, 2019), and if the protocol allows continuation, the team would note that SSRIs may reduce the response (Johnson et al., 2008; Goodwin et al., 2023). St. John's wort should be identified as a product to avoid (Johnson et al., 2008), and the person should know why. The antihistamine would be checked for interactions by the physician or pharmacist. Cannabis use would be recorded and discussed openly, without judgement, so that the person will disclose all substances; the protocol may specify a period without it. Each decision is shared between the person, the screening physician and, for prescribed medicines, the prescriber.

7.5 Who May Be Excluded Unfairly

Every exclusion criterion shifts risk from the person who is treated to the person who is turned away, who loses the potential benefit. Criteria that were set for trials may exclude people who could be treated safely in practice, and some exclusions fall more heavily on particular groups. This part of the section examines three sources of unfair exclusion.

The first is the narrowness of trial samples. Michaels and colleagues (2018) reviewed 18 psychedelic studies from 1993 to 2017 with 282 participants and found that 82.3 percent were non-Hispanic White, so reported outcomes may not generalize to all ethnic and cultural groups. A 2024 systematic review of 39 studies found that 85.0 percent of participants in pooled data were non-Hispanic White, with greater proportions of ethnic minoritized participants in studies published since 2018, particularly in the United States (Hughes & Garcia-Romeu, 2024); in one 2023 phase 3 trial of MDMA-assisted therapy, 26.9 percent of participants identified as Hispanic or Latino and 33.7 percent as other than White (Mitchell et al., 2023). Lesson 12 develops trial diversity, cost and public funding. The second source is criteria that are contested, such as the 140/90 mmHg blood pressure limit (Nayak et al., 2026) and the exclusion of everyone with a relative who has bipolar disorder (Downey et al., 2024), and the requirement to stop antidepressants that some people cannot stop safely (Goodwin et al., 2023; Tap et al., 2025). The third is practical. Protocols release people to the care of a friend or family member (Johnson et al., 2008) and require several preparation and integration visits and a full day for dosing, which disadvantages people who live alone, cannot take time off work or live far from a treatment site. The accordion below separates these kinds of exclusion.

Exclusions that protect the personv

Criteria such as a current psychotic disorder, a QTc above 500 ms, or active suicidal intent exclude people for whom the risk is high and the evidence is reasonably clear. They are the criteria least likely to be relaxed in practice, although the person still needs another form of care.

Exclusions that protect the trialv

Criteria that make a sample uniform, such as excluding common comorbid conditions, make an effect easier to detect. When treatment moves into practice, these criteria may no longer be needed, and Williams and colleagues (2026) examine which medical criteria should carry over into hospital psychiatry.

Barriers that are logisticalv

The lack of a companion, distance or the cost of time off are barriers that a service can often remove. Johnson et al. (2008) describe the option of an overnight stay at the research site, and Health Canada (2022) states that lodging should be available on the day of administration. Treating a logistical barrier as an exclusion would disadvantage the people who face it.

Interactive 6.1 asks you to apply the criteria in this section to seven hypothetical referrals. For each one, choose the decision that the stated criteria support, then check your choices and read the feedback, which notes where the criteria themselves are contested.

Interactive 6.1Screening decisions for hypothetical referrals

All referrals are hypothetical. For each, choose the decision that the criteria described in this section support.

Screening reduces risk, and the exercise shows that it also involves judgement about evidence, timing and fairness. However careful it is, screening cannot remove every risk: Sections 1 and 2 showed that screened participants still have difficult experiences, blood pressure excursions and, occasionally, serious adverse events. Section 4 turns to how teams manage these events when they occur, and how support is offered to people who use psychedelics outside clinics.

Key Takeaways

  • 7.1 Psychiatric criteria commonly exclude people with a current or past psychotic disorder, bipolar I or II disorder, a first- or second-degree relative with these disorders or clinically significant suicide risk, and healthy-volunteer studies also exclude recent substance dependence; trials adapt these rules to their population and question. Medical screening uses a history, examination, 12-lead ECG and blood tests to find conditions the drug could worsen, with drug-specific criteria such as QTc limits, potassium and QT-prolonging medicines for ibogaine.
  • 7.2 Thresholds such as 140/90 mmHg for resting blood pressure and 450 ms (men) or 470 ms (women) for QTc are cautious conventions that divide a continuous measure, and a 2026 preprint proposes a limit below 160/100 mmHg for psilocybin. Judging a threshold means asking what harm it prevents, what evidence links the measure to that harm in the population treated and what happens to the people it excludes, and the answers differ by drug.
  • 7.3 Stabilization treats or resolves an acute problem, such as a crisis, uncontrolled blood pressure or withdrawal from alcohol or benzodiazepines, before treatment; a deferral means the person will be reassessed, while an exclusion means the protocol's criteria are not met. Active suicidal intent or a recent attempt makes a person ineligible at this time and calls for an immediate safety assessment and crisis care, and structured suicide risk assessment with the C-SSRS is part of screening.
  • 7.4 A medication review records prescribed, over-the-counter, herbal and non-prescribed substances and checks each for interactions, including serotonergic antidepressants, lithium, monoamine oxidase inhibitors, St. John's wort and drugs that prolong the QT interval. Antidepressant washouts have been common in trials, but withdrawal is frequent, can be severe and can mimic relapse, and one small open-label study gave psilocybin alongside an SSRI, so any taper is a decision for the person and their prescriber.
  • 7.5 Narrow trial samples, contested criteria, such as the 140/90 mmHg limit, blanket family-history exclusion and required washouts, and practical demands such as a companion at discharge can exclude people unfairly. Separating exclusions that protect the person from those that protect the trial and from logistical barriers that a service can remove shows which criteria should carry into practice, as the screening decisions in Interactive 6.1 illustrate.

Reflection

A hypothetical 58-year-old with treatment-resistant depression is referred to a psilocybin study whose protocol follows Johnson, Richards and Griffiths (2008) and the COMP360 phase 2b trial. Four features stand out: resting blood pressure averages 148/92 mmHg across four readings on two days; their father was diagnosed with bipolar I disorder at age 45; they take venlafaxine, a serotonergic antidepressant, and the protocol requires stopping it at least two weeks before baseline; and they live alone with no one to accompany them home. For each feature, state whether it leads to deferral, exclusion or a solvable barrier under these criteria, and argue whether any of the criteria should be revisited, citing evidence from this lesson.

Model answerThe blood pressure of 148/92 mmHg exceeds the protocol's 140/90 limit, so it leads to deferral: hypertension can often be treated and remeasured. A 2026 preprint of 536 Johns Hopkins sessions argues that a limit of 160/100 mmHg may be safe for psilocybin, which suggests this criterion deserves revisiting once the analysis is peer reviewed. The father's bipolar I disorder meets the first-degree family history exclusion, so under these criteria the person is excluded. Downey and colleagues argue for stratified assessment, in which a parent's onset at 45, in a participant who is already 58, might weigh differently from an early onset in the relative of a young participant, but the protocol as written excludes. Venlafaxine creates a decision for the person and their prescriber: tapering is required, and Horowitz and Taylor show that withdrawal is common and can mimic relapse, so the taper may need months. It is a deferral while the taper is planned, and early evidence, from the open-label study of Goodwin and colleagues (2023) on psilocybin with an SSRI and a 2025 scoping review of 18 studies (Tap et al., 2025), suggests that future protocols might allow continuation, although venlafaxine is a serotonin and noradrenaline reuptake inhibitor that the open-label study did not include. Living alone is a solvable barrier, since overnight lodging meets the guidance of Johnson and colleagues and Health Canada. Of the four, the blood pressure and antidepressant criteria seem most open to revision, while the family history criterion needs better evidence before it changes.

Minimum 20 characters required.

✓ Reflection saved
Knowledge Check: this section

Question 1: Which blood pressure criterion did Johnson, Richards and Griffiths (2008) describe for excluding volunteers?

Their criterion excluded volunteers whose resting pressure exceeded 140/90 mmHg, averaged across four assessments on at least two separate days. The 160/100 mmHg figure is the broader limit proposed in a 2026 preprint, which, as of October 2026, had not been peer reviewed.

Question 2: A hypothetical person with depression made a suicide attempt three weeks ago and reports current suicidal intent. Which screening decision do the criteria in this lesson support?

Trials exclude people at clinically significant risk of suicide (Goodwin et al., 2022), so this person is ineligible at this time, and the immediate need is a safety assessment and referral to crisis care, such as the 9-8-8 Suicide Crisis Helpline; any later reassessment would follow only after that care. A permanent exclusion goes beyond what the criteria say, and proceeding would ignore the evidence of suicidality after dosing.

Question 3: What concern about antidepressant tapering do Horowitz and Taylor (2019) raise that bears on trial washout periods?

They report that SSRI withdrawal occurs often, can be severe and may be mistaken for a return of depression, and that tapers over months succeed better than the two- to four-week tapers in guidelines. Trial washouts of about two weeks are therefore demanding, and Goodwin et al. (2023) tested psilocybin given alongside an SSRI.

Question 4: A hypothetical person meets every criterion but lives alone and has no one to accompany them home after dosing. How does this lesson classify that issue?

Johnson et al. (2008) describe an overnight stay as an alternative to release to a companion, and Health Canada (2022) states that lodging should be available on the day of dosing. Treating the lack of a companion as an exclusion would disadvantage people who live alone.
Section 4 of 5

Managing Difficult Experiences and Medical Events: Response, Aftercare and Support Outside Clinics

⏱ Estimated reading time: 40 minutes
Section 4 of 5

Managing Difficult Experiences and Medical Events

Response, aftercare and support outside clinics.

The response ladder

From reassurance to emergency transfer

1. Presence and reassurance
2. Adjust the setting
3. Medical assessment
4. Rescue medication
5. Emergency transfer

Published guidance makes reassurance the first response and medication a last resort (Johnson et al., 2008).

Support first

Principles during a difficult experience

  • Offer strong personal support and reassurance first.
  • Avoid arguing the person out of the experience.
  • Use touch only as agreed before dosing.
  • Keep two trained people present, and watch for medical signs.

Sources: safety guidelines (Johnson et al., 2008); expectations for trials (Health Canada, 2022).

Rescue and emergencies

Prepared for rare events

Rescue medication

A benzodiazepine for severe anxiety; haloperidol is not a rescue medication (Johnson et al., 2008). Events needing medical intervention were rare in research settings (Hinkle et al., 2024).

Emergency protocol

Physician on site for the duration of effects and a contingency plan (Health Canada, 2022).

Aftercare

Discharge, follow-up and safety plans

Session day

Discharge to a briefed companion or overnight lodging (Johnson et al., 2008).

Next day to weeks

Follow-up meeting, then check-ins and integration (Health Canada, 2022).

Months

Watch for suicidality in people who have not responded and for extended difficulties; review the safety plan (Compass Pathways, 2021).

Outside clinics

Support within clear limits

Peer support lines

Fireside Project, as of October 2026: peer support by phone or text for callers in the United States; not clinical or crisis care (Fireside Project, 2026).

Sanctuary spaces

In 2026, Shambhala's Sanctuary sat beside medical services (Shambhala Music Festival, 2026); ANKORS has offered harm reduction there since 2003 (Mema et al., 2018).

User-reported resources describe experiences and cannot establish safety.

The law in Canada

Limits on practitioners

  • As of October 2026, possession without authorization is an offence under subsection 4(1) of the Controlled Drugs and Substances Act.
  • Section 21 of the Criminal Code makes those who aid or abet a party to the offence.
  • The Good Samaritan Drug Overdose Act (2017) protects people who seek help during an overdose from possession charges.
Bringing it together

How risk is managed

  • Know the drug, and time monitoring to it.
  • Select and prepare the person, and defer when timing is wrong.
  • Plan for rare events, and continue care for months.

Next: the reflection and the final assessment below.

Content note

This section discusses medical emergencies and follow-up for suicidal thoughts and behaviour after treatment. Support is available at any time from the 9-8-8 Suicide Crisis Helpline (call or text 9-8-8) and, for Indigenous people across Canada, the Hope for Wellness Help Line (1-855-242-3310).

Introduction

Screening lowers risk without removing it. Section 1 showed that blood pressure rises during psilocybin sessions, with systolic pressure crossing 170 mmHg in about 6 percent of the sessions pooled in one research centre's 2026 preprint, and Section 2 showed that serious psychiatric events occur in a small proportion of patients even in trials. In research settings, difficult moments during a session have mostly been psychological and have passed with support (Johnson et al., 2008), and adverse events needing medical intervention have been rare (Hinkle et al., 2024); medical events still need a response that has been planned before the session starts. Health Canada's expectations for clinical trials state that contingency plans should be established for potential serious adverse events (Health Canada, 2022). This section follows the response from the least to the most intensive step, then turns to discharge, aftercare and the support available to people who use psychedelics outside clinics. Figure 6.6 shows the steps.

Learning Objectives

  • 8.1 Describe the stepwise approach to supporting a person through a difficult experience during a session, and explain why reassurance comes first.
  • 8.2 Explain when rescue medication is used, which medicines published guidelines recommend, and how rarely they have been needed.
  • 8.3 Describe the elements of an emergency protocol for medical events, and evaluate a session record against a safety checklist.
  • 8.4 State discharge criteria and the components of aftercare, including follow-up for suicidality and extended difficulties.
  • 9.1 Describe peer support lines and festival sanctuary services in Canada and the United States, and explain what each can and cannot do.
  • 9.2 State the protection that the Good Samaritan Drug Overdose Act provides and the legal limits that apply to regulated practitioners in Canada.
1. Presence andreassurance 2. Adjust thesetting, groundthe person 3. Medicalassessmentphysician checksmeasurements 4. Rescuemedicationa last resort 5. Emergencytransferper the plan Responding to a difficult moment or a medical event Published guidance puts reassurance first and medication last.
Figure 6.6. The escalation of a response during a session, from interpersonal support to emergency transfer, drawn from the safety guidelines of Johnson, Richards and Griffiths (2008) and Health Canada's expectations for trials (2022).

8.1 Supporting a Person Through a Difficult Experience

Difficult experiences during a session include fear, panic, confusion, grief and painful memories. Lesson 5 described how often they occur, and Lesson 7 describes the therapist's role in the session; this part concerns the first two steps in Figure 6.6.

Johnson, Richards and Griffiths (2008) state that the appropriate first response to acute distress is strong personal support and reassurance. They warn that attempts to "talk down" a person may be counterproductive and aggravate a difficult reaction, and they describe holding the person's hand as a powerful form of reassurance. They encourage participants to let the experience unfold and to move toward difficult material when it arises, and they recommend at least two monitors so that the participant is never alone when one of them steps out. In their own studies, reassurance had been sufficient to handle every case of acute psychological distress among 54 volunteers who received high doses of psilocybin. This guidance rests mainly on experience in research settings. The flip cards below summarize the principles that recur in published guidance.

Never aloneClick to explore
Reassurance firstClick to explore
Support, without steeringClick to explore
Touch only as agreedClick to explore
Watch for medical signsClick to explore

The second step adjusts the setting, which can include reducing light and noise, changing or pausing music, helping the person change position, offering water or a blanket, and grounding attention in breathing or in the room. Lesson 5 reviewed the evidence on music and environment. When these steps are not enough, or when measurements suggest a medical problem, the response moves to a physician's assessment and, rarely, to medication.

8.2 Rescue Medication

A rescue medication is a drug given to relieve severe distress or a dangerous physical effect during a session. Johnson, Richards and Griffiths (2008) describe pharmacological intervention as a last resort that should rarely, if ever, be needed. For severe anxiety, they recommend an oral benzodiazepine, such as diazepam, as the intervention of choice. They state that antipsychotic medicines such as risperidone or olanzapine should be available, while noting that their effects may be abrupt, unpleasant and intense, that haloperidol should not be used as a rescue medication, and that ketanserin, a 5-HT2A antagonist, might serve as one, although it is not approved in the United States. Antihypertensive medicine should be immediately available in case blood pressure exceeds the protocol's limits.

Frequency data support this description. In one research centre's pooled data, reported in a 2026 preprint, antihypertensive medicine was given in one of 536 psilocybin sessions (Nayak et al., 2026). In the meta-analysis by Hinkle and colleagues (2024), non-serious adverse events that required medical intervention, such as paranoia or headache, were similarly rare to serious events. The box below explains why teams still prepare for them.

Why prepare for events that rarely happen

A sedating medicine relieves severe anxiety, and it may also alter the experience on which the treatment depends, so the decision balances the person's immediate safety against the therapeutic aim. The consent process tells the person in advance when such medicines might be offered (Lesson 7).

Preparing for rare events is a matter of probability over many sessions. At a hypothetical service that runs ten sessions a week, or about 520 a year, an event that occurs once in 500 sessions has about a 65 percent chance of occurring at least once in a year, so the medicine, the dose, the person authorized to give it and the record that documents it must be settled in the protocol before the first session.

8.3 Emergency Protocols for Medical Events

An emergency protocol states, before any session, who is responsible, what is measured and when, what each threshold triggers and how a person is transferred to hospital. Health Canada (2022) expects a licensed physician to be readily available on site for the duration of the drug's effects in trials of psychedelic-assisted psychotherapy, contingency plans for serious adverse events, and the reporting of serious unexpected adverse drug reactions to Health Canada. In Alberta, licensed psychedelic drug treatment services must report on complaints and must report critical incidents, defined as incidents that cause or threaten to cause serious injury or death (Government of Alberta, 2022, 2025). Table 6.7 sets out the medical events discussed in this lesson with the prepared responses described in the sources.

Table 6.7. Medical events discussed in this lesson, with the prepared response described in each source.

EventHow it is detectedPrepared response in the sources
Blood pressure excursion during psilocybin or MDMAMeasurements timed to the peak (about 90 minutes for psilocybin)Recheck; antihypertensive medicine available (Johnson et al., 2008); most excursions are brief (Nayak et al., 2026, preprint)
Blood pressure rise after esketamineMeasurement before the dose and at about 40 minutesMonitoring for at least two hours after each dose (Janssen, 2026)
QTc prolongation after ibogaineRepeated 12-lead ECGs for at least 24 hours, continued if a cardiologist judges it necessaryMagnesium infusion above 500 ms and transfer to a coronary care unit for continuous monitoring if needed (Knuijver et al., 2022)
Rising body temperature with MDMATemperature measurement during the session (Vizeli & Liechti, 2017)Medical assessment; hyperpyrexia and hyponatremia need hospital care (Hall & Henry, 2006; Campbell & Rosner, 2008)
SeizureObservation; risk factors identified at screeningScreening for lithium and for alcohol or benzodiazepine withdrawal (Nayak et al., 2021; Alper et al., 2012); emergency transfer

A checklist turns a protocol into steps that a team can verify. Interactive 6.2 presents the record of a hypothetical psilocybin session in an authorized Canadian trial. Read the record, decide whether each item on the checklist was met, and then check your answers; the feedback sorts any gaps by when they would have to be fixed.

Interactive 6.2Session safety checklist
Hypothetical session record. A participant receives psilocybin in an authorized clinical trial. Consent, including consent to supportive touch on the hand and shoulder, was obtained at screening and reviewed at the last preparation visit while she was sober. Her medication list was reviewed at screening and again on the morning of dosing. Her resting blood pressure before dosing was 132/84 mmHg, within the protocol limit of 140/90. Two trained therapists were present throughout, and when one left the room the other stayed. The study physician was working at a hospital across town and could be reached by phone. Antihypertensive medicine and a benzodiazepine were kept in the session room. The protocol's contingency plan named the nearest emergency department and the procedure for transfer. Blood pressure was measured before dosing and again at the end of the session, six hours later. She was discharged at 4 p.m. once the effects had resolved, and she took a taxi home alone. She was given the lead therapist's phone number, and a follow-up visit was booked for the next day, with check-ins planned for weeks 1, 2 and 4.

A session can meet most requirements and still leave gaps that matter, such as a physician who cannot reach the room quickly, measurements that miss the peak and a discharge without support. Closing the last of these gaps depends on what happens after the person leaves the clinic.

8.4 Discharge and Aftercare

Safety continues after the acute effects end. Discharge criteria decide when a person may leave, and aftercare covers the months that follow.

8.4.1 Discharge

Johnson, Richards and Griffiths (2008) describe releasing participants only after the effects of the drug have resolved, into the care of a friend or family member whom staff have oriented to provide emotional support, or keeping them overnight at the research site. Participants are told not to drive or engage in other potentially dangerous activities for the rest of the day, and they receive a number to call. Health Canada (2022) states that lodging should be available on the day the drug is given. For esketamine, the prescribing information requires monitoring for at least two hours and advises against driving until the next day after a restful sleep (Janssen, 2026).

8.4.2 Aftercare and Follow-Up

Johnson, Richards and Griffiths (2008) recommend one or more meetings after each session, typically the next day, and they advise asking about perceptual disturbances at follow-up (Section 2). Health Canada (2022) expects check-in visits in the days and weeks after administration because mental health may worsen after treatment sessions. The timing of the events in Section 2 shows why follow-up must extend beyond the first few days: in the COMP360 phase 2b trial, most serious suicidality events occurred at least a week after the session, and all suicidal behaviours occurred at least a month after it, in people who had not responded (Compass Pathways, 2021). Follow-up therefore tracks response as well as safety, and a person who has not improved needs a plan for further care (Figure 6.7).

Session day Next day Weeks 1 to 4 Months 1 to 3+ Discharge aftereffects resolve,to a companionor overnight stay Follow-up meeting;ask about distressand perceptions Check-ins andintegration(Lesson 7) Watch for suicidalityin non-responders andextended difficulties;refer when needed Sources: Johnson et al. (2008); Health Canada (2022); Compass Pathways (2021); Evans et al. (2023).
Figure 6.7. An aftercare timeline that follows published guidance and the timing of adverse events reported in trials.

Two further elements complete aftercare. The first is a safety plan, a written list of warning signs, coping strategies, people to contact and services to use if suicidal thoughts arise. In Veterans Health Administration emergency departments in the United States, the Safety Planning Intervention with at least two follow-up calls was associated with suicidal behaviour in 3.03 percent of patients over six months, against 5.29 percent with usual care (odds ratio 0.56) (Stanley et al., 2018). That evidence comes from another setting, but it supports building a plan during preparation (Lesson 7) and reviewing it at follow-up. The second element is a referral pathway for extended difficulties, which can last for months (Section 2; Lesson 7).

9.1 Support Outside Clinical Settings

Lesson 1 showed that most psychedelic use happens outside clinics, without screening, monitoring or aftercare. Harm reduction is the public health approach that aims to reduce the harms of drug use without requiring that people stop using, and HSCI 402 develops harm reduction services, including drug checking. This part of the section describes the services that support people outside clinics and the legal position of practitioners in Canada; it describes services and principles and gives no advice on using any drug.

9.1.1 Peer Support Lines

Fireside Project, a non-profit organization in the United States, launched its Psychedelic Support Line in 2021. As of October 2026, it offers free, confidential peer support by call or text at 62-FIRESIDE (623-473-7433) from 11 a.m. to 11 p.m. Pacific time every day, staffed by trained volunteers, and it serves callers in the United States only, with a stated aim of expanding to Canada. It states that it does not provide mental health, clinical or medical services, that it is not a suicide hotline, and that people in an emergency should call emergency services (Fireside Project, 2026); in Canada, these are 9-1-1 and the 9-8-8 Suicide Crisis Helpline. Pleet and colleagues (2023) analyzed data from 884 callers to the line: 65.9 percent said the call had de-escalated them from psychological distress, 29.3 percent said that without it they might have been harmed, and 10.8 percent said they might have gone to an emergency room. These are callers' own judgements without a comparison group, so they suggest benefit without measuring it.

9.1.2 Festival Sanctuary Services

Sanctuary services are quiet spaces at events where trained staff or volunteers support people through difficult experiences. At the Shambhala Music Festival in rural British Columbia, ANKORS, a harm reduction organization based in Nelson, has provided harm reduction services since 2003, including drug checking (Mema et al., 2018). In October 2026, the festival's website described a Sanctuary next to its medical services, open 24 hours a day and staffed by experienced professionals, for anyone feeling stressed, overwhelmed or isolated or experiencing anxiety, panic, hallucinations, delusions or dissociation (Shambhala Music Festival, 2026). In Toronto, TRIP!, a peer harm reduction project, has offered peer harm reduction at events and drop-in sessions for about 30 years, as it described its work in 2025 (TRIP!, 2026). In the United States, the Zendo Project has run a support space at the Burning Man event since 2012, as its website described in 2026, and trains volunteers to support people at events without trying to fix or guide their experience (Zendo Project, 2026).

9.1.3 User-Facing Resources

Online resources reach people before and during use. TripSit offers a live chat with volunteers, who state that they hold no professional certification, along with drug factsheets and a chart of drug combinations (TripSit, 2026). PsychonautWiki describes itself as a community-driven online encyclopedia of psychonautics (PsychonautWiki, 2026), and Lesson 1 discussed its Subjective Effect Index. MAPS Canada, a volunteer-run organization, offers public education and psychedelic safety resources (MAPS Canada, 2026). These resources record what people who use psychedelics report and publish harm reduction information; they cannot establish the efficacy or safety of any drug. Table 6.8 compares the services described here.

Table 6.8. Support services for people who use psychedelics outside clinics, with what each offers and what it cannot do, as described by each organization in 2026.

ServiceWhat it offersWhat it cannot do
Fireside Project support linePeer support by phone or text, daily 11 a.m. to 11 p.m. PacificClinical, medical or crisis care, or service to callers in Canada (as of October 2026)
Festival sanctuary spaces (Shambhala; Zendo Project)A calm space and in-person support at an eventFollow-up after the event
Peer event programs (TRIP!)Peer harm reduction education and supplies at events and drop-insMedical assessment or treatment
Online resources (TripSit, PsychonautWiki)Volunteer chat and user-reported informationEstablish safety or efficacy, or replace medical care
Emergency services (9-1-1)Medical assessment, treatment and transportPeer support

9.2 Legal Protections and Limits in Canada

Fear of police can delay a call for help. Canada's Good Samaritan Drug Overdose Act, in force since 4 May 2017, protects people who seek emergency help during an overdose, including the person who has overdosed and others at the scene, from charges for simple possession of a controlled substance; it does not protect against charges for trafficking or production or against outstanding warrants (Health Canada, 2026). The box below explains a different legal limit, which applies to regulated practitioners.

The legal limits on practitioners in Canada

This box gives legal information, not legal advice. Under subsection 4(1) of the Controlled Drugs and Substances Act, "Except as authorized under the regulations, no person shall possess a substance included in Schedule I, II or III." As of October 2026, psilocybin, psilocin, LSD, DMT and mescaline are listed in Schedule III, and MDMA and ketamine in Schedule I. Under section 21 of the Criminal Code, everyone is a party to an offence who actually commits it, does or omits to do anything for the purpose of aiding any person to commit it, or abets any person in committing it.

Taken together, these provisions mean that a regulated professional who provides preparation or integration support for the unauthorized use of a scheduled psychedelic may be at legal risk of being a party to the offence of possession, in addition to the professional consequences that a regulatory college may impose. Section 56 of the Act allows the Minister of Health to grant exemptions. Exemptions, clinical trials and the Special Access Program are the authorized routes that Lesson 11 describes; since the federal Controlled Substances Regulations (SOR/2025-242) came into force on 1 October 2026, the Special Access Program for restricted drugs such as psilocybin and MDMA has operated under those regulations, which absorbed the earlier section 56 class exemption for that program.

Ibogaine is not listed in the Act and is on Health Canada's Prescription Drug List (Section 1). Lesson 7 explains how the law shapes preparation and integration practice.

Applying this lesson: Alberta's licensed psychedelic treatment services

Since 16 January 2023, Alberta has required providers of psychedelic drug treatment for psychiatric disorders to hold a licence, to appoint a psychiatrist as medical director, to have the drug prescribed only by a psychiatrist or a physician consulting a psychiatrist, to have psychotherapy delivered by qualified regulated professionals such as psychiatrists and clinical psychologists, to have authorized professionals monitor and care for patients while they are in an altered state of consciousness, and to report on complaints and critical incidents (Government of Alberta, 2022); its licensing page still described the licensing requirement and psychiatrist oversight in October 2026 (Government of Alberta, 2025). Using this lesson, (1) name two safety elements that these requirements address directly, (2) name three elements they do not specify, which a provider's protocol would need to set out, and (3) write the rule you would include for one of them, with its source.

Suggested answer: (1) Monitoring during altered states addresses the session safety of Sections 1 and 4, and critical incident reporting supports the adverse event surveillance that Hinkle et al. (2024) found weak in research. (2) The summary does not specify screening criteria (Section 3), the timing of blood pressure measurements and the thresholds that trigger action (Sections 1 and 4), or discharge and follow-up rules, including follow-up for suicidality (Sections 2 and 4). (3) A follow-up rule could read: "Every patient has a follow-up meeting the day after each session and check-ins over the following weeks, with an assessment of response and of suicidal thoughts at each contact," based on Johnson et al. (2008), Health Canada (2022) and the timing reported by Compass Pathways (2021).

This section has followed the response to difficulty from a hand held in reassurance to an emergency transfer, and from discharge to follow-up over months. Together with the physical risks of Section 1, the psychiatric risks of Section 2 and the screening of Section 3, it describes how psychedelic-assisted therapy manages risk: by knowing the drug, selecting and preparing the person, controlling the setting, planning for rare events and continuing care after the session. The reflection and the final assessment below ask you to bring these parts together.

Key Takeaways

  • 8.1 The first response to acute distress is strong personal support and reassurance, with at least two monitors so that the person is never alone, touch only as agreed, and no attempt to talk the person down. The second step adjusts the setting and grounds the person's attention, and measurements continue because distress can mask a medical problem.
  • 8.2 Rescue medication is a last resort: an oral benzodiazepine such as diazepam for severe anxiety, antipsychotics available although their effects can be abrupt, no haloperidol, and antihypertensive medicine on hand. It has rarely been needed, with antihypertensive medicine given in one of 536 pooled psilocybin sessions reported in a 2026 preprint, but over hundreds of sessions a year a rare event becomes likely, so the medicine, dose and authority to give it are settled before the first session.
  • 8.3 An emergency protocol states who is responsible, what is measured and when, what each threshold triggers and how a person is transferred to hospital, and Health Canada expects a physician readily available on site for the duration of the effects and contingency plans in trials. Checking a session record against a safety checklist shows that a session can meet most requirements and still leave gaps, such as an off-site physician or measurements that miss the peak.
  • 8.4 Discharge follows the resolution of the drug's effects, into the care of an oriented companion or overnight lodging, with no driving that day and a number to call. Aftercare includes a next-day meeting, check-ins over the following weeks, a written safety plan and a referral pathway for extended difficulties, and follow-up must extend for months because suicidal behaviour in the phase 2b trial occurred at least a month after dosing in people who had not responded.
  • 9.1 Peer support lines such as Fireside Project, festival sanctuary spaces such as Shambhala's, peer programs such as TRIP! and online resources such as TripSit support people who use psychedelics outside clinics. Each works within clear limits: none provides clinical or crisis care, sanctuary spaces offer no follow-up, and online resources cannot establish safety, so medical emergencies in Canada go to 9-1-1 and suicidal crises to 9-8-8.
  • 9.2 Canada's Good Samaritan Drug Overdose Act protects people who seek emergency help during an overdose from charges for simple possession, but not from trafficking or production charges or outstanding warrants. A regulated professional who supports the unauthorized use of a scheduled psychedelic may be at legal risk as a party to possession under subsection 4(1) of the Controlled Drugs and Substances Act and section 21 of the Criminal Code, and exemptions, clinical trials and the Special Access Program are the authorized routes.

Reflection

A hypothetical friend tells you they intend to take psilocybin mushrooms at a music festival in British Columbia and asks what support exists if something goes wrong. You are a health sciences student, not a clinician, and you will not give advice on using the drug. Using only the services and principles described in Section 4 (a festival sanctuary space next to medical services, such as the one Shambhala describes; Fireside Project's peer support line, which served callers in the United States only in October 2026; 9-1-1 and the Good Samaritan Drug Overdose Act; and user-facing resources such as TripSit), describe what you would tell your friend about the support available and what each source can and cannot do.

Model answerI would start by saying that I cannot tell them how to use the drug or whether it is safe for them, and that the decision is theirs. I would then describe what exists. Some festivals, including Shambhala, run a sanctuary space beside their medical services, where experienced staff support people who feel overwhelmed, anxious or confused; it offers a calm place and in-person help during the event, but no follow-up afterwards. Fireside Project runs a peer support line for people in the United States, but in October 2026 it did not take calls from Canada, so in British Columbia the 9-8-8 Suicide Crisis Helpline is the line to use for thoughts of suicide. For anything that looks medical, such as chest pain, a seizure, confusion with overheating or someone who cannot be woken, the right call is 9-1-1, and the Good Samaritan Drug Overdose Act protects people who call for help during an overdose from simple possession charges, though not from other charges. Online resources such as TripSit offer volunteer chat and user-reported information, which can describe other people's experiences but cannot establish that anything is safe. Finally, I would mention that if distress lasts for days afterwards, a doctor or counsellor can help.

Minimum 20 characters required.

✓ Reflection saved
Knowledge Check: this section

Question 1: According to Johnson, Richards and Griffiths (2008), what is the appropriate first response when a participant becomes acutely distressed during a session?

The guidelines place interpersonal support and reassurance first and describe medication as a last resort that should rarely be needed. Arguing a person out of what they perceive, or trying to "talk them down", may aggravate a difficult reaction.

Question 2: What did Health Canada's December 2022 expectations for clinical trials of psychedelic-assisted psychotherapy say about physicians?

The notice expects a licensed physician to be readily available on site for the duration of the drug's effects, together with at least two trained therapists during dosing. A physician who can be reached only by phone across town would not meet this expectation, as Interactive 6.2 shows.

Question 3: Which statement about the Fireside Project's support line is accurate as of October 2026?

Fireside Project offers free peer support by call or text, staffed by trained volunteers, from 11 a.m. to 11 p.m. Pacific time, states that it does not provide clinical or medical services and is not a suicide hotline, and serves callers in the United States only as of October 2026. In Canada, emergencies go to 9-1-1 and suicidal crises to 9-8-8.

Question 4: What protection does Canada's Good Samaritan Drug Overdose Act (in force since 4 May 2017) provide?

The Act protects people who seek emergency help during an overdose, including the person who overdosed and others at the scene, from charges for simple possession. It does not cover trafficking, production or outstanding warrants, and it gives no protection for supplying drugs.
Section 5 of 5

Final Assessment

⏱ Estimated time: 30 minutes

Bringing It All Together

This lesson has examined the risks of psychedelics and how psychedelic-assisted therapy manages them. Section 1 showed that physical risks follow from pharmacology and setting: transient rises in blood pressure that protocols monitor at the right times, MDMA hyperthermia and hyponatremia that concentrate in hot and crowded events, the QT prolongation behind deaths associated with ibogaine, the unresolved 5-HT2B question for repeated dosing and ketamine cystitis with frequent use. Section 2 showed that psychiatric risks are real and uneven, from psychosis and mania in vulnerable people to suicidality in depression trials and extended difficulties that can last for years, and that each type of study sees only part of the picture.

Sections 3 and 4 turned to the response. Screening uses psychiatric and medical criteria, thresholds and medication review to identify people at high risk, and it involves judgement about evidence, timing and fairness. Management during and after a session moves from reassurance to emergency transfer, and aftercare continues for months because some serious events occur weeks after dosing. Outside clinics, peer support lines and sanctuary services offer support within clear limits, and the law sets limits on what regulated practitioners may do.

Key Takeaways from this lesson

  1. Psilocybin raised systolic blood pressure by about 19 mmHg on average in supervised studies, with the largest changes 60 to 90 minutes after dosing (a 2026 review), and esketamine's rise peaks at about 40 minutes, so monitoring must be timed to the drug.
  2. MDMA can cause hyperthermia and hyponatremia, and heat, crowding, exertion, heavy fluid intake and unknown doses explain why these harms concentrate outside clinics.
  3. Ibogaine and noribogaine lengthen the QT interval through hERG channel inhibition seen in cell studies, and a QTc corrected by Bazett's or Fridericia's formula can fall on either side of a threshold; most deaths in a 2012 review involved pre-existing heart disease or other drugs, and a 2026 review notes arrhythmias in people without known heart disease.
  4. The link between 5-HT2B receptors and valvular heart disease is supported by cell evidence and one small human study for MDMA, and a 2023 review found no study designed to test it for repeated classic psychedelic dosing, so for these drugs the risk remains largely speculative; ketamine-associated cystitis rises with dose and frequency of use.
  5. Psychosis appears uncommon in trials, on mostly low-quality evidence (a 2025 meta-analysis), while population studies link severe reactions to hallucinogens with later psychotic and manic disorders. Suicidal ideation, suicidal behaviour or self-injury occurred in all dose groups of the 2022 COMP360 phase 2b trial, and extended difficulties can last for more than a year in some people who report them. Trials exclude the people at highest risk and are too small to detect rare harms.
  6. Risk differences, relative risks and numbers needed to harm size an imbalance in adverse events, and their wide confidence intervals in small trials, like the rule of three when no events occur, show how much remains compatible with the data.
  7. Screening distinguishes exclusion from deferral, and some criteria, such as the 140/90 mmHg limit, family history and antidepressant washouts, rest on limited evidence and may exclude people unfairly.
  8. Reassurance is the first response to distress, medication is a last resort, and emergency protocols, discharge to a companion or lodging, and follow-up over months complete the safety plan.
  9. Peer support lines, festival sanctuary services and user-facing resources help people outside clinics within clear limits, the Good Samaritan Drug Overdose Act protects people who call for help during an overdose from simple possession charges, and Canadian law can expose regulated practitioners who support unauthorized use to legal risk.

Core Concepts Reviewed

Section 1: blood pressure excursions and their timing, hyperthermia, hyponatremia and vasopressin, the QT interval and its correction, hERG inhibition and torsades de pointes, 5-HT2B receptors and valvular heart disease, and ketamine-associated cystitis.

Section 2: psychosis and mania with personal and family history, suicidality signals in trials, risk differences and numbers needed to harm, hallucinogen persisting perception disorder, extended difficulties and the rule of three.

Section 3: psychiatric and medical exclusion criteria, blood pressure and QTc thresholds, stabilization and deferral, suicide risk assessment, medication review and antidepressant tapering, and unfair exclusion.

Section 4: de-escalation and reassurance, rescue medication, emergency protocols, discharge criteria, aftercare and safety plans, peer support lines, sanctuary services, the Good Samaritan Drug Overdose Act and the legal limits on practitioners.

The final reflection asks you to bring the four sections together in the safety section of a treatment protocol.

Reflection

Design the safety section of a protocol for a hypothetical psilocybin-assisted therapy program for treatment-resistant depression in British Columbia, operating through an authorized route. Address four parts: (1) screening, including at least two psychiatric and two medical criteria; (2) the dosing session, including staffing, measurements and their timing, and rescue medication; (3) discharge; and (4) follow-up over the months after dosing. Cite at least five sources from this lesson, and identify one criterion you would relax and one you would keep, with reasons.

Model answerScreening would exclude people with a current or past psychotic disorder or bipolar I disorder and people at clinically significant risk of suicide, who would be ineligible at this time and referred for immediate crisis care (Johnson et al., 2008; Goodwin et al., 2022). Medically, a physician would review history, examination, a 12-lead ECG and blood tests, exclude established cardiovascular disease and defer people with resting blood pressure above the protocol limit (Health Canada, 2022; Johnson et al., 2008). A medication review would identify lithium and serotonergic antidepressants and involve the prescriber in any taper, planned slowly because withdrawal can mimic relapse (Horowitz & Taylor, 2019). During dosing, two trained therapists would be present with a physician on site for the duration of the effects (Health Canada, 2022), blood pressure would be measured at least hourly to capture the peak at about 90 minutes (Nayak et al., 2026), and a benzodiazepine and an antihypertensive would be on hand as a last resort (Johnson et al., 2008). Discharge would follow resolution of effects, to an oriented companion or overnight lodging. Follow-up would include a next-day meeting, check-ins over weeks and continued monitoring of non-responders for at least three months, with a safety plan (Compass Pathways, 2021; Stanley et al., 2018). I would relax the 140/90 mmHg limit toward 160/100 mmHg once the pooled analysis is peer reviewed, and I would keep the exclusion of personal psychotic disorder, where the evidence of harm is clearest.

Minimum 30 characters required.

✓ Reflection saved

Final Knowledge Assessment

Final Assessment, this lesson: Safety, Screening and Risk Management (15 Questions)

Question 1: A hypothetical service plans to give esketamine and psilocybin in different programs. Which monitoring plan matches the evidence in Section 1?

The esketamine label requires reassessment at about 40 minutes and at least two hours of monitoring, while psilocybin's blood pressure peaks at about 90 minutes and returns near baseline by 300 minutes. A plan built for one drug can miss the other's peak.

Question 2: How do the MDMA harms in Section 1 and the extended difficulties in Section 2 point to the same lesson about setting?

Parrott (2012) linked larger temperature rises in clubs to activity, heat and overcrowding, and Evans et al. (2023) found that a guided setting predicted a narrower range of extended difficulties. Neither finding supports the view that supervision causes harm.

Question 3: A hypothetical 47-year-old man who takes methadone for opioid use disorder asks to join an ibogaine study that uses the criteria of Knuijver et al. (2022). His screening QTc is 462 ms. Which decision and reason fit the evidence?

The study excluded men with a QTc above 450 ms, and ibogaine lengthened the QTc by about 95 to 100 ms in a typical participant, with effects lasting beyond 24 hours. The 500 ms threshold applies to monitoring during treatment. Methadone did not itself exclude people from that study, whose participants were switched to morphine before dosing, but the QTc limit applied at screening.

Question 4: Hinkle et al. (2024) found serious adverse events in about 4 percent of trial participants with neuropsychiatric conditions and systematic adverse event assessment in only 23.5 percent of recent studies. What follows for consent and public claims?

Serious events occurred among patients, not healthy volunteers, and incomplete assessment means some events may have been missed, so claims of no serious adverse events overstate the evidence. Accurate consent describes these risks honestly.

Question 5: A hypothetical screening team considers excluding a person whose aunt has bipolar I disorder. Which statement best reflects this lesson?

Johnson et al. (2008) exclude people with a first- or second-degree relative with psychotic or bipolar disorder, and an aunt is a second-degree relative. Downey et al. (2024) argue for stratified assessment, and they note that the evidence on family history comes mainly from case studies and surveys.

Question 6: How should a team treat the recommendation of Nayak et al. (2026) to broaden blood pressure eligibility for psilocybin to below 160/100 mmHg?

As of October 2026, the analysis was a preprint from a single research centre, and its authors keep the exclusion of established cardiovascular disease. Until review and replication, teams follow their protocols while noting that the 140/90 mmHg limit has limited empirical support.

Question 7: Which follow-up schedule best fits both Health Canada's 2022 expectations and the timing of suicidality events in the COMP360 phase 2b trial?

Health Canada expects check-ins in the days and weeks after dosing, and the sponsor reported that suicidal behaviours occurred at least a month after dosing in non-responders. A single call or one week of follow-up would miss that window.

Question 8: Which statement about rescue medication matches the safety guidelines of Johnson, Richards and Griffiths (2008)?

The guidelines describe medication as a last resort, recommend an oral benzodiazepine such as diazepam for severe anxiety, keep antipsychotics such as risperidone or olanzapine available while warning that their effects can be abrupt, and advise against haloperidol as a rescue medication.

Question 9: A hypothetical trial of 150 participants reports no cases of a serious adverse event. What is the approximate upper limit of the 95 percent confidence interval for its true risk, and what caution applies?

By the rule of three, 3 ÷ 150 = 0.02, or 2 percent (Eypasch et al., 1995). The bound is meaningful only if adverse events were assessed systematically, which fewer than a quarter of recent psychedelic studies did (Hinkle et al., 2024).

Question 10: A hypothetical client cites PsychonautWiki and TripSit as proof that combining two drugs is safe. How should a practitioner describe these sources?

PsychonautWiki describes itself as a community-driven encyclopedia, and TripSit's volunteers state that they hold no professional certification. Their information records what people who use drugs report and cannot establish the efficacy or safety of any drug or combination.

Question 11: A hypothetical registered counsellor in British Columbia offers preparation sessions for clients planning to use psilocybin obtained without authorization. What legal position does this lesson describe?

Psilocybin is listed in Schedule III, possession without authorization is an offence under subsection 4(1), and section 21 makes anyone who aids or abets an offence a party to it. The Good Samaritan Act covers people seeking help during an overdose and does not address this situation.

Question 12: What does the evidence in Section 1 suggest about the bladder risks of ketamine?

Winstock et al. (2012) found urinary symptoms linked to both dose and frequency, with improvement after stopping in about half of respondents, and Shahani et al. (2007) found sterile urine cultures. The esketamine prescribing information reports no esketamine-related interstitial cystitis in its studies.

Question 13: Why do the authors of the Ontario study of mania after hallucinogen acute care (Myran et al., 2025b) limit the generalizability of their findings?

The exposure was an emergency visit or hospitalization involving hallucinogens, which marks a severe reaction, so the results may not apply to most people who use hallucinogens and never need acute care. The study used health records and followed people for three years.

Question 14: In a hypothetical trial session, the study physician works at a hospital across town and can be reached by phone. When must this gap be closed, according to Health Canada's 2022 expectations?

Health Canada expects a licensed physician to be readily available on site for the duration of the drug's effects, so the arrangement must be in place before dosing. Waiting for an excursion would leave no physician on site when one is needed.

Question 15: A hypothetical person referred for psilocybin takes lithium prescribed by a psychiatrist. Which response integrates Sections 3 and 4 with Lesson 3?

An analysis of online reports found seizures in 47 percent of 62 reports of classic psychedelics taken with lithium (Nayak et al., 2021), and whether lithium can be stopped safely is the prescriber's decision. Stopping it abruptly or dosing with a rescue plan would not address the risk.
✦ Complete the final reflection above before submitting

Congratulations!

You have successfully completed this lesson: Safety, Screening and Risk Management.

You can now explain the main physical and psychiatric risks of psychedelics and the evidence behind each, calculate corrected QT intervals and numbers needed to harm, apply screening criteria while recognizing their limits, and describe how a team responds to difficult experiences and medical events during and after a session and how support is offered outside clinics.

Lesson 7 follows the therapeutic process itself, from models of psychedelic-assisted therapy through preparation, consent and safety planning to the dosing session and integration, including the legal limits on preparation and integration support for unregulated use in Canada.

Continue to Lesson 7 →
Reference

Glossary: Key Terms, People & Frameworks

📚 Reference page, available throughout the lesson

Terms, tools and people from this lesson on the safety of psychedelics, screening and the management of risk.

Core Concepts
Adverse event Any unfavourable medical occurrence in a person receiving a treatment, whether or not the treatment caused it. A treatment-emergent adverse event begins or worsens after treatment starts.
Serious adverse event An adverse event that is fatal or life-threatening, requires hospitalization or causes lasting disability. In a 2024 meta-analysis of psychedelic studies, about 4 percent of participants with neuropsychiatric conditions had one.
Hyperthermia A rise in core body temperature above its normal range. MDMA increases heat production and delays sweating, and heat, crowding and exertion add to the rise.
Hyponatremia An abnormally low concentration of sodium in the blood. With MDMA it results from vasopressin release, increased thirst and heavy fluid intake.
Arginine vasopressin The antidiuretic hormone that signals the kidneys to retain water. MDMA causes its release, which contributes to hyponatremia.
QT interval The time on an electrocardiogram from the start of the QRS complex to the end of the T wave, covering the activation and recovery of the ventricles.
QTc The QT interval corrected for heart rate, for example by Bazett's or Fridericia's formula. A QTc above 500 ms is considered highly abnormal.
Torsades de pointes A fast, irregular rhythm of the ventricles that can be life-threatening. Its risk rises when drugs such as ibogaine lengthen the QT interval.
hERG channel A potassium channel in heart muscle cells that carries the current for repolarization. Ibogaine and noribogaine inhibit it in cell studies.
Noribogaine The main metabolite of ibogaine, with a half-life of 28 to 49 hours, which also inhibits hERG channels and extends the period of cardiac risk.
5-HT2B receptor A serotonin receptor found on heart valve cells. Drugs that activate it, such as fenfluramine, have been linked to valvular heart disease.
Valvular heart disease Damage to the heart valves that makes them leak or narrow. Drug-induced forms have been linked to 5-HT2B receptor activation.
Ketamine-associated ulcerative cystitis Severe inflammation of the bladder lining in people who use ketamine frequently, described in a Toronto case series in 2007.
Psychosis A state in which a person loses contact with shared reality through hallucinations, delusions or disorganized thinking.
Mania A period of abnormally elevated or irritable mood with increased energy, reduced need for sleep and impaired judgement, which defines bipolar I disorder.
Suicidal ideation Thoughts of ending one's life, ranging from a passive wish to be dead to an active plan. Trials measure it with standard scales such as the Columbia Suicide Severity Rating Scale, and some repeat it at every visit.
Hallucinogen persisting perception disorder The re-experiencing, after use has stopped, of perceptual distortions first experienced while intoxicated, causing distress or impairment. Reviews describe it as genuine but uncommon, and its incidence has not been established.
Extended difficulties Psychological difficulties such as anxiety, depersonalization or existential struggle that last weeks to years after a psychedelic experience.
Stabilization Treating or resolving an acute problem, such as uncontrolled blood pressure or withdrawal from alcohol, before psychedelic treatment begins. It leads to deferral and reassessment; active suicidal intent or a recent suicide attempt instead makes a person ineligible at this time and calls for immediate crisis care.
Exclusion criterion A characteristic that makes a person ineligible for a protocol, such as a past psychotic disorder. Some criteria protect the person and others protect the validity of a trial.
Washout A period during which a medicine is tapered and stopped before a trial treatment. Psilocybin trials have commonly required antidepressant washouts of about two weeks.
Rescue medication A drug given to relieve severe distress or a dangerous physical effect during a session, such as a benzodiazepine. It is a last resort.
Safety plan A written, prioritized list of warning signs, coping strategies, people to contact and services to use if suicidal thoughts arise.
Number needed to harm The reciprocal of a positive risk difference: how many people would need to receive a treatment for one additional person to have an adverse event.
Rule of three A shortcut stating that if no events occur among n people, the upper limit of the 95 percent confidence interval for the risk is about 3 divided by n.
Sanctuary service A quiet space at a festival or event where trained staff or volunteers support people through difficult experiences, usually beside medical services.
Frameworks & Tools
Bazett formula QTc equals the measured QT interval divided by the square root of the RR interval. It tends to give overlong values at heart rates above about 85 beats per minute.
Fridericia formula QTc equals the measured QT interval divided by the cube root of the RR interval. The Dutch ibogaine study used it to measure QTc during monitoring.
Columbia Suicide Severity Rating Scale A structured interview (C-SSRS) that assesses the presence, intensity and history of suicidal thoughts and behaviour in trials.
Data and safety monitoring board An independent committee that reviews unblinded safety data during a trial and can recommend changes or a halt.
Safety Planning Intervention A brief intervention that builds a personal safety plan, associated with less suicidal behaviour after emergency department visits when combined with follow-up calls.
Good Samaritan Drug Overdose Act A federal law in force since 4 May 2017 that protects people who seek emergency help during an overdose from charges for simple possession.
Health Canada risk management expectations A December 2022 notice for trials of psychedelic-assisted psychotherapy expecting physician involvement in screening, two therapists during dosing, a physician on site and consent for touch.
Key People
Matthew W. Johnson Psychopharmacologist who, at Johns Hopkins, led the 2008 safety guidelines for human hallucinogen research with William A. Richards and Roland R. Griffiths.
Roland R. Griffiths Johns Hopkins researcher who co-authored the 2008 safety guidelines and the 2016 survey of challenging experiences with psilocybin mushrooms.
Sidney Cohen Psychiatrist whose 1960 survey of researchers estimated rates of prolonged psychotic reactions and suicide attempts after LSD given in research and treatment.
Kenneth R. Alper Lead author of the 2012 review of 19 deaths temporally associated with ibogaine between 1990 and 2008.
Guy M. Goodwin Psychiatrist and lead author of the COMP360 phase 2b trial of psilocybin in treatment-resistant depression (2022) and its open-label study with SSRIs (2023).
Daniel T. Myran Ontario researcher who led population cohort studies of psychotic and manic disorders after hallucinogen-related acute care (2025).
Bryan L. Roth Pharmacologist who co-authored the studies linking 5-HT2B receptor activation to drug-induced valvular heart disease and to MDMA's effects on valve cells.
No matching entries. Try a different search term.